STEMCELLS INC. voll im Trend. - 500 Beiträge pro Seite

[gerdass]

Kleine Wert mit einem großen Potential!!!


http://www.stemcellsinc.com/news/090114.html
Embryonale Stammzellen haben das Potential, sich in jede der mehr als 200 Zellarten des menschlichen Körpers zu verwandeln. Diese embryonalen Zellen gewinnen Forscher aus dem Inneren eines drei bis fünf Tage alten Embryos, in diesem Stadium der Entwicklung als Blastozyste oder Bläschen bezeichnet.

Quelle der Stammzellen ist die innere Zellmasse, die an einer Seite des Bläschens anliegt und aus denen sich - mit Hilfe des sie umgebenden Trophhoblasten - der neue Organismus entwickelt. Embryonale Stammzellen gelten als pluripotent und nicht als totipotent, weil sie sich ohne Trophoblasten als Schutz und Nahrungsquelle nicht in einen Organismus entwickeln können.

Es ist aber bereits gelungen, aus Stammzellen von Mäusen Keimzellen zu entwickeln. Es gibt viele humane Linien embryonaler Stammzellen, isoliert aus überzähligen Embryonen. Im Februar 2004 haben südkoreanische Forscher gezeigt, daß sich die Zellen auch durch Klonen gewinnen lassen.


Da diese Thematik sehr umfangreich ist, werden weitere Informationen noch folgen.

Man kann sich aber z.B. auf dieser Seite grundlegende Informationen über die Möglichkeiten der Stammzell- und Klontechnologie bekommen: http://www.aerztezeitung.de/medizin/stammzellen/default.asp?…" target="_blank" rel="nofollow ugc noopener">http://www.aerztezeitung.de/medizin/stammzellen/default.asp?…

Stemcells Inc.

[tomcat17]

Da würde ich mir lieber Advanced Cell Technologies ins Depot legen dort klingt die Story erfolgsversprechender. Haben Verfahren zur Herstellung von künstlichen Blut entwickelt. Sehr interessant bei dem engen Blutkonservernmarkt, Blutkrankheiten und auf dem Hintergrund, dass Obama in den USA die Stammzellenforschung weiter vorantreiben will.

Gruss tomcat17

[gerdass]

Antwort auf Beitrag Nr.: 36.433.564 von tomcat17 am 23.01.09 10:49:52

Der ganze Bereich wird buhmen.
Sicherlich haben kleinere Werte mehr Aufholpotenzial.

[gerdass]

[gerdass]

Antwort auf Beitrag Nr.: 36.433.564 von tomcat17 am 23.01.09 10:49:52

Das ist noch der kleine Unterschied.
Marktkapitalisierung 204,12 Mio.

[Sugar2000]

Liebe Leute,

ich muss hier was klarstellen!
STEMCELLS forscht auf dem Gebiet der "adulten" Stammzellen, nicht wie #1 geschrieben, im Bereich der embryonalen Stammzellen!

Auf dem Gebiet der embryonalen Stammzellen ist derzeit Geron am weitesten! Heute kamen News...

23.01.2009 06:02
Geron Receives FDA Clearance to Begin World’s First Human Clinical Trial of Embryonic Stem Cell-Based Therapy Geron to Study GRNOPC1 in Patients With Acute Spinal Cord Injury

Conference Call and Video Webcast Set for 6:00 a.m. PST/9:00 a.m. EST

Geron Corporation (News) (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.

The clearance enables Geron to move forward with the world’s first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with ”complete” American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.

”The FDA’s clearance of our GRNOPC1 IND is one of Geron’s most significant accomplishments to date,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and CEO. ”This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient’s injured spinal cord.”

GRNOPC1, Geron’s lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).

”The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury,” said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. ”Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year.”

The GRNOPC1 Clinical Program

Patients eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury. Geron has selected up to seven U.S. medical centers as candidates to participate in this study and in planned protocol extensions. The sites will be identified as they come online and are ready to enroll subjects into the study.

Although the primary endpoint of the trial is safety, the protocol includes secondary endpoints to assess efficacy, such as improved neuromuscular control or sensation in the trunk or lower extremities. Once safety in this patient population has been established and the FDA reviews clinical data in conjunction with additional data from ongoing animal studies, Geron plans to seek FDA approval to extend the study to increase the dose of GRNOPC1, enroll subjects with complete cervical injuries and expand the trial to include patients with severe incomplete (ASIA grade B or C) injuries to enable access to the therapy for as broad a population of severe spinal cord-injured patients as is medically appropriate.

Preclinical Evidence of Safety, Tolerability and Efficacy

Geron submitted evidence of the safety, tolerability and efficacy of GRNOPC1 to the FDA in a 21,000-page IND application that described 24 separate animal studies requiring the production of more than five billion GRNOPC1 cells. Included in the safety package were studies that showed no evidence of teratoma formation 12 months after injection of clinical grade GRNOPC1 into the injured spinal cord of rats and mice. Other studies documented the absence of significant migration of the injected cells outside the spinal cord, allodynia induction (increased neuropathic pain due to the injected cells), systemic toxicity or increased mortality in animals receiving GRNOPC1.

In vitro studies have shown that GRNOPC1 is minimally recognized by the human immune system. GRNOPC1 is not recognized in vitro by allogeneic sera, NK cells or T cells (Journal of Neuroimmunology, Vol. 192, 2007). These immune-privileged characteristics of the hESC-derived cells allow a clinical trial design that incorporates a limited course of low-dose immunosuppression and provide the rationale for an off-the-shelf, allogeneic cell therapy.

Also included in the IND application were published studies supporting the utility of GRNOPC1 for the treatment of spinal cord injury. Those studies showed that administration of GRNOPC1 significantly improved locomotor activity and kinematic scores of animals with spinal cord injuries when injected seven days after the injury (Journal of Neuroscience, Vol. 25, 2005). Histological examination of the injured spinal cords treated with GRNOPC1 showed improved axon survival and extensive remyelination surrounding the rat axons. These effects of GRNOPC1 were present nine months after a single injection of cells. In these nine-month studies, the cells were shown to migrate and fill the lesion cavity, with bundles of myelinated axons crossing the injury site.

Production and Qualification of GRNOPC1

GRNOPC1 is produced using current Good Manufacturing Practices (cGMP) in Geron’s manufacturing facilities. Geron’s GRNOPC1 production process and clean-room suites have been inspected and licensed by the state of California. The cells are derived from the H1 human embryonic stem cell line, which was created before August 9, 2001. Studies using this line qualify for U.S. federal research funding, although no federal funding was received for the development of the product or to support the clinical trial.

Geron’s H1 hESC master cell bank is fully qualified for human use and was shown to be karyotypically normal and free of measurable contaminants of human or animal origin. Production of GRNOPC1 from undifferentiated hESCs in the master cell bank uses qualified reagents and a standardized protocol developed at Geron over the past three years. Each manufacturing run of GRNOPC1 is subjected to standardized quality control testing to ensure viability, sterility and appropriate cellular composition before release for clinical use. GRNOPC1 product that has passed all such specifications and has been released is available for the approved clinical trial. The current production scale can supply product needs through pivotal clinical trials. The existing master cell bank could potentially supply sufficient starting material for GRNOPC1 to commercially supply the U.S. acute spinal cord injury market for more than 20 years.

Intellectual Property

The production and commercialization of GRNOPC1 is protected by a portfolio of patent rights owned by or exclusively licensed to Geron. Patent rights owned by Geron protect key technologies developed at Geron for the scalable manufacturing of hESCs, as well as the production of neural cells by differentiation of hESCs. The fundamental patents covering hESCs are exclusively licensed to Geron from the Wisconsin Alumni Research Foundation (WARF) for the production of neural cells, cardiomyocytes and pancreatic islets for therapeutic applications. The validity of these patents was recently confirmed by the U.S. Patent and Trademark Office in a re-examination proceeding. Geron funded the original research at the University of Wisconsin-Madison that led to the first isolation of hESCs. The production of oligodendrocytes from hESCs is covered by patent rights exclusively licensed to Geron from the University of California. These patent rights cover technology developed in a research collaboration between Geron and University of California scientists.

Conference Call and Video Webcast

Thomas B. Okarma, Ph.D., M.D., will host a conference call and video Webcast presentation for investors and the media at 6:00 a.m. PST/9:00 a.m. EST today. Participants can access the conference call via telephone by dialing 866-783-2145 (U.S.) or 857-350-1604 (international). The passcode is 89631672. The video Webcast presentation is available at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetail… All participants are encouraged to view Dr. Okarma’s presentation on the Internet. The video Webcast will also be accessible through a link that is posted on the home page of Geron’s Web site at http://www.geron.com. Participants are encouraged to log on at least 15 minutes prior to the beginning of the presentation in order to download any necessary software. The video Webcast will be available for replay through February 23, 2009.

Background information about human embryonic stem cells, GRNOPC1 and the spinal cord injury clinical trial can be found at http://eon.businesswire.com/news/eon/20090122006356/en.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem (hESC) cell-based therapeutics. The company has received FDA clearance to begin the world’s first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury. For more information, visit www.geron.com.

This news release may contain forward-looking statements made pursuant to the ”safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of Geron’s human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron’s periodic reports, including the quarterly report on Form 10-Q for the quarter ended September 30, 2008.



Contacts:

Russo Partners, LLC
David Schull, 858-717-2310 (Media)
[e-mail]
or
Geron
Anna Krassowska, 650-473-7765
Investor and Media Relations
[e-mail]

[gerdass]

Antwort auf Beitrag Nr.: 36.433.873 von Sugar2000 am 23.01.09 11:16:57

Es steht da nicht geschrieben, das sie im Bereich der embryonalen Stammzellen forschen.


Danke für die Werbung

Auch Geron wird seinen Weg finden müssen.

[gerdass]

Dawson James Securities Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
PALO ALTO, Calif., (January 14, 2009) – StemCells, Inc. (NASDAQ: STEM) today announced that Dawson James Securities, Inc. has initiated research coverage on the Company with a “speculative buy” rating and a target price of $3.00 per share. The report was written by Stephen M. Dunn, Director of Research, who covers both public and private companies in the biotechnology, pharmaceutical and medical device sectors. The full report can be accessed on the Dawson James website, www.dawsonjames.com.

According to their website, Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology. Dawson James acted as co-lead placement agent in the Company’s $20 million registered direct offering in November 2008.

About StemCells, Inc.
StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The Company’s product development programs seek to repair or repopulate CNS and liver tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of HuCNS-SC ® cells, its highly purified, expandable population of human neural stem cells. StemCells is conducting a six patient Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL), which is expected to be completed in January 2009. NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative disease that affects infants and young children. StemCells has also received approval from the US Food and Drug Administration (FDA) to initiate a Phase I clinical trial of the HuCNS-SC cells to treat Pelizaeus-Merzbacher Disease (PMD), also a rare and fatal brain disorder that mainly affects young children. StemCells owns or has exclusive rights to more than 50 issued or allowed U.S. patents and more than 150 granted or allowed non-U.S. patents. Further information about the Company is available on its web site at: www.stemcellsinc.com .

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (the “Company”) and its ability to conduct clinical trials as well as its research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainty as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in NCL, PMD or in future clinical trials of proposed therapies for other diseases or conditions despite the novel and unproven nature of the Company’s technologies; uncertainties about whether the Company will receive the necessary support of a clinical study center and its ethics board to initiate a clinical trial in PMD; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s manufacturing capabilities given its increasing preclinical and clinical commitments; and other factors that are described under the heading “Risk Factors” in Item 1A of Part II of the Company’s Quarterly Report on Form 10-Q.

#########################

CONTACT: StemCells, Inc.
Rodney Young
Chief Financial Officer
650-475-3100, Ext. 105
[e-mail]

SOURCE: StemCells, Inc.

[Sugar2000]

Antwort auf Beitrag Nr.: 36.433.961 von gerdass am 23.01.09 11:24:21

Sorry, aber das deutet sehr darauf hin...

Kleine Wert mit einem großen Potential!!!
http://www.stemcellsinc.com/news/090114.html
Embryonale Stammzellen haben das Potential

Finde das schon irreführend...

[Sugar2000]

Antwort auf Beitrag Nr.: 36.434.029 von gerdass am 23.01.09 11:30:40

zudem habe ich nichts gegen STEMCELLS... bin dort auch investiert!
Nur wir sollten bei den Fakten bleiben!

[gerdass]

Antwort auf Beitrag Nr.: 36.434.106 von Sugar2000 am 23.01.09 11:36:31

Hast RECHT.

Das ist alles erst in den Startlöchern. Noch kann man sich hier und da noch sehr gut positionieren.
Dieses Thema wird uns über Jahre Kurssteigerungen erhoffen lassen.
http://topics.edition.cnn.com/topics/stem_cell_research

[gerdass]

Antwort auf Beitrag Nr.: 36.434.086 von Sugar2000 am 23.01.09 11:35:12

Da ist schon was drann. Noch ist der Wert klein und Potenzial sehe auch ich hier.Hier, wie auch bei vergleichbaren Werten ist Geduld von sehr großem Vorteil

[gerdass]

Antwort auf Beitrag Nr.: 36.434.086 von Sugar2000 am 23.01.09 11:35:12

Hier ist ein kleiner Wert, mit möglichem Potenzial.
http://www.wallstreet-online.deimg.wallstreet-online.de/disk…

[Sugar2000]

Antwort auf Beitrag Nr.: 36.434.274 von gerdass am 23.01.09 11:49:43

Ich habe die 3 Werte im Auge bzw. im Depot:

Geron, Stemcells und Aastrom

[Sugar2000]

Antwort auf Beitrag Nr.: 36.434.274 von gerdass am 23.01.09 11:49:43

bist du gerade rein?!
12:11:10 4,37 400 Geron in Frankfurt?

[gerdass]

Antwort auf Beitrag Nr.: 36.434.655 von Sugar2000 am 23.01.09 12:19:38

Bei Geron bin ich noch nicht drin.

[Sugar2000]

vom Aktionär:

Geron: Kursfeuerwerk bei Stammzellen-Aktien
Frank Phillipps



Geron darf erstmals Therapien auf Basis embryonaler Stammzellen am Menschen testen. Mediziner träumen von revolutionären Therapien, Aktionäre von exorbitanten Kurssprüngen. Zumindest Letztere kommen schon kurzfristig auf ihre Kosten.


Kurz nach Börseneröffnung in den USA notiert die Aktie von Geron über 30 Prozent im Plus. Und das aus gutem Grund: Die US-Gesundheitsbehörde FDA hat dem US-Unternehmen erlaubt, ein Medikament, das auf Basis embryonaler Stammzellen entwickelt wurde, erstmals am Menschen zu testen. Im Sommer dieses Jahres sollen die Tests starten. Dann werden zehn querschnittsgelähmte Patienten mit Rückenmarkszellen behandelt, die aus embryonalen Stammzellen gezüchtet wurden. In der ersten Phase der Studien geht es darum, die Sicherheit der Arznei zu belegen und eine gesundheitliche Gefährdung der Patienten auszuschließen.

Auf den Marktführer setzen

Vom Geron-Erfolg profitierten auch die Papiere anderer Stammzellenforscher. So notiert etwa die ohnehin in den letzten Wochen sehr gut gelaufene Aktie von Stemcells ebenso deutlich im Plus wie der Anteilschein von Aastrom Biosciences. Favorit von DER AKTIONÄR ist eindeutig die Aktie von Geron. Das Unternehmen, das über ein weiteres Standbein in der Onkologie verfügt, ist unangefochtener Marktführer im Bereich der embryonalen Stammzellen und Stand bereits auf der Top-Empfehlungsliste des AKTIONÄRS für 2008. Da die Erlaubnis für die Tests am Menschen nun etwas später kam als gedacht und das Papier in den Strudel der Finanzkrise geriet, wurde die Aktie zwischenzeitlich ausgestoppt.

Geduld und Mut gefragt

Wer in Geron investiert, sollte jedoch bedenken, dass die Therapien auf Stammzellen-Basis noch in den Kinderschuhen stecken und noch Jahre von einer möglichen Zulassung entfernt sind. Zudem haben sich die Aktien aus diesem Bereich in den letzten Jahren als extrem volatil erwiesen. Anleger, die sich bei Geron engagieren sollten dementsprechend über einen langfristigen Investitionshorizont verfügen und gute Nerven mitbringen.

[v3a]

ich bin schon lange drin. habe viele höhen und tiefen erlebt.
aber was jetzt abgeht ?
viele grüße v3a

[gerdass]

[jub2]

Bin bei Stem mit einer kleinen Pos dabei... Geron wäre noch eine schöne Aktie die man im Depot haben sollte. Nur was ist ein angemessener Wert für die beiden Aktien?

[gerdass]

Antwort auf Beitrag Nr.: 36.439.965 von jub2 am 23.01.09 21:27:14

nehm von beiden etwas

[jub2]

Antwort auf Beitrag Nr.: 36.440.290 von gerdass am 23.01.09 22:11:06

haha, ja leider geht mir im Gegensatz zu Dir so langsam das Spielgeld aus - alles schon z.T. aussichtsreich investiert, sonst hätte ich gestern nicht nur STEM gekauft.

Ich behalte die Sache im Auge. Wie hoch hier das Aufwärtspotential wohl sein wird?

Vielleicht schichte ich mein Depot ein wenig um. Ich denke da mal am WE drüber nach.

[gerdass]

Antwort auf Beitrag Nr.: 36.440.486 von jub2 am 23.01.09 22:41:12

Hier hat es erst angefangen. Stammzellen-Forschung wird die Zukunft über eine längere Zeit bleiben und liegen voll im Trend.

Was um Gottes Willen soll man an der >Börse zur Zeit kaufen?

Autowerte? Banken? Maschienenbauer?

Ich bin mir sicher, dass die Börse diesea Jahr soetwas von runterknallen wird.

Allerdings mit einer Ausnahme, es wird der Forschungsbereich sein.

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 36.437.361 von v3a am 23.01.09 16:49:16

hallo,
ich habe ebenfalls das auf und ab mitgemacht und bin jetzt beim durchschnittskurs angekommen.

chart sieht ja langfristig wegen steigenden durchschnittslinien sehr gut aus.

da ich selbst von einer querschnittslähmung betroffen bin setze ich sehr auf stammzellenforschung.

übrigens seit zwei jahren gibts in köln eine therapie mit körpereigenen adulten stammzellen.

info unter
http://www.xcell-center.de/

gruß
ted

[gerdass]

Antwort auf Beitrag Nr.: 36.441.603 von TEDDYLOVE am 24.01.09 12:20:12

Ich drücke dir beide Daumen. Die USA wird es möglich machen können.

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 36.441.912 von gerdass am 24.01.09 13:48:10

danke!
ich wünsche allen die noch investiert sind glück, denn stemcells sollten jetzt mit obamas programm besser laufen als in der vergangenheit.

ted

[gerdass]

Antwort auf Beitrag Nr.: 36.443.307 von TEDDYLOVE am 24.01.09 21:53:25

da ich selbst von einer querschnittslähmung betroffen bin setze ich sehr auf stammzellenforschung

Dafür drücke ich dir beide Daumen.

Der Kurs wird langfristig nur eine Richtung wahrnehmen.

[gerdass]

Durch leichte Gewinnmitn.durchaus akzeptabel für einen Freitag in den USA.

[gerdass]

Aktueller Kurs 2,53

Währung US Dollar

Kurszeit 22:00



Differenz +0,38 (+17,67%)

Eröffnungskurs 2,24

Tageshöchstkurs 2,89

Tagestiefkurs 2,24

Marktkapitalisierung 240,20 Mio.

Letzter Schlusskurs 2,15

Schlusskurs-Datum 22.01.

Volumen 59,89 Mio.

Gehandelte Stücke 27 Mio.

Preisfeststellungen 33.698

[gerdass]

Zur HP von stemcellsinc.com
http://www.stemcellsinc.com/news/090114.html





INTRADAY - CHART-Fa.stemcellsinc

[gerdass]

http://stemcells.nih.gov/info/basics/basics1.asp

[gerdass]

STEMCELLS INC.mit Höhrn u. Tiefen.

[gerdass]

Antwort auf Beitrag Nr.: 36.437.347 von Sugar2000 am 23.01.09 16:48:29

Das ist eine gute Einschätzung zu Geron.

Geduld und Mut gefragt
...................................................................


Das gilt allerdings auch für viele andere Firmen aus dem Bereich.

[gerdass]

17450 Stücke wurden lediglich am Freitag in Deutschland gehandelt

[gerdass]

[gerdass]

Kleiner Verschnauferl
morgen drüben zweistellig


Yes we can !!!

[gerdass]

Schaun wir mal, wie es aussieht, wenn Qualität am steigen ist.

[gerdass]

das mag heute was werden

[TEDDYLOVE]

na da ging ja nachbörslich die post ab, stem + 66%.
aastrom hat zahlen gebracht und stieg nachbörslich 80%.
montag ist in deutschland biotechtag

gruß
ted

[gerdass]

Antwort auf Beitrag Nr.: 36.723.110 von TEDDYLOVE am 07.03.09 22:52:48

Ein Genuß, für den, der schon drin ist

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 36.724.363 von gerdass am 08.03.09 14:00:53

stimmt
hab mich doch schon was geärgert letzte woche nicht noch ein paar stücke nachzulegen zumal die aktie genau auf die 200 und 300 tagelinie korrigierte.

der anstieg hat aber auch etwas mit einer meldung über obama bei forbs.com zu tun.

Shares of Geron soared Friday evening, up more than 36% on word that President Barack Obama will sign an executive order Monday lifting President Bush’s limit on embryonic stem-cell research funding. StemCells Inc. also rose more than 53% on the news. Cytori Therapeutics was up 23%.

http://www.forbes.com/2009/03/07/biotech-stem-cells-au…

gruß
ted

[gerdass]

Antwort auf Beitrag Nr.: 36.724.421 von TEDDYLOVE am 08.03.09 14:17:02

Oft gelingt es nicht alles ideal zu machen
ich muß zu geben,ich habe auch hier einige Stücke
die größere Hebelwirkung haben allerdings kleinere Werte
in ihnen habe ich mehr investiert

[jensdab]

Obama macht den Weg frei: Stammzell-Aktien schießen bis 43% nach oben
von Volkmar Michler


Das ist die langersehnte Wende. Nur wenige Wochen nach dem Amtsantritt von Obama ist jetzt das eingetreten, worauf Taipan schon im letzten November mitten im US-Wahlkampf hingewiesen hat: „Ein Sektor, der stark von einem Obama-Sieg profitieren wird, ist die Stammzellforschung."

Seit gestern wissen wir, in welche Richtung dies gehen wird: Obama stellt sich eindeutig hinter die Stammzellforschung und hebt die vom Vorgänger verfügten massiven Beschränkungen auf. „Wir werden Wissenschaftler, die diese Forschung betreiben, nach Kräften unterstützen", so Obama gestern in einer präsidialen Verfügung. Damit haben Stammzell-Firmen jetzt mit einem Schlag Zugang zu Forschungs-Millionen , die ihnen unter Bush jahrelange verwährt waren.

Die Stammzellforschung ist einer der wissenschaftlich aussichtsreichsten, aber politisch und gesellschaftlich umstrittensten Biotech-Sektoren. Unter Bush, welcher der ultra-konservativen und religiösen Rechten in den USA angehört, konnte sich die Stammzellforschung nicht so weiterentwickeln, wie es möglich gewesen wäre.

Mit eindeutigem Blick auf Bush sagte Obama gestern, dass dies die „falsche Wahl zwischen vernünftiger Wissenschaft und moralischen Werten" sei.

Stammzell-Aktien mit gigantischem Nachholpotenzial

Damit ist für die Stammzell-Forschung unter Obama die neue Richtung klar. Für Stammzell-Aktien auch. Kaum war gestern die Nachricht draußen, schossen einige Stammzell-Aktien um bis zu 43% nach oben. Die von Taipan im November empfohlene Stammzell-Aktie, die damals bei 3,23 US$ notierte, hat mittlerweile sogar ihr 1-Jahres-Kursziel bei 4,50 US$ längst erreicht. Nein, die Aktie wurde kurz nach der Wahl von Obama regelrecht nach oben katapultiert - auf über 8,47 US$.

Gegenüber unserer ursprünglichen Empfehlung ein unglaublicher Anstieg von 162% innerhalb weniger Wochen. Durch die miese Börsenphase der letzten Wochen ist die Aktie dann aber wieder dort angelangt, wo unsere ursprüngliche Empfehlung lag - bei deutlich unter 4,00 US$.

Bis gestern. Denn nach der Obama-Freigabe der Stammzell-Forschung hat diese Stammzell-Aktie sofort einen Sprung bis 5,20 US$ gemacht. Dabei hat das Unternehmen immer noch eine winzige Börsenbewertung von gerade einmal 306 Mio. US$. Vor wenigen Jahren als die Stammzell-Forschung unter Bush noch nicht so düster aussah, notierte die Aktie übrigens schon mal bei knapp 17,00 US$ - Sie sehen, welches Potenzial in dieser über die Bush-Jahre völlig vernachlässigten Branche steckt.

1,98-US$-Stammzell-Aktie wieder auf dem Sprung in Richtung 5,00 US$

Andere Stammzell-Aktien, die ich beobachte, sind noch winziger. Ein Unternehmen, dass ich zum Beispiel seit Jahren verfolge, notiert jetzt gerade einmal 1,98 US$ - gestern hat es einen unglaublichen Satz von über 43% gemacht. An der Börse wird dieses Stammzell-Unternehmen trotz dieses Riesensprung gerade einmal mit 131 Mio. US$ bewertet. Stellen Sie sich vor, was passiert, wenn hier jetzt massive Forschungsgelder fließen. Ich kann mir das gut vorstellen. Denn vor wenigen Jahren notiert dieses winziges Stammzell-Unternehmen schon mal bei knapp 7 US$ - das sind immer noch rund 250% über dem jetzigen Kurs!

Was hatten wir in Taipan im November letzten Jahres noch geschrieben! „Die Stammzellbranche hat unter Obama das größte Nachholpotential, wenn die Forschung wieder aktiv gefördert wird." Genau das ist jetzt eingetreten. Jetzt steht die gesamte Branche vor einer Neubewertung - und mit ihr einige wenige unter 2,00 US$ bzw. unter 5,00 US$ notierende Stammzell-Aktien. Die werden wir für Taipan jetzt wieder ins Depot nehmen, solange sie noch so tief notieren. Für weitere Informationen dazu klicken Sie auf Taipan

Gute Kurse wünscht Ihnen

Volkmar Michler

*************************************************************


Möglicherweise ist mit der obigen Beschreibung Stemcell gemeint mit einer MK von ca. 130 Mill. Euro? Wenn die ins Depot von Taipan aufgenommen wurden, könnte das den Kurs zumindest kurzfristig beflügeln.

[sneake]

guten morgen zusammen

[Sugar2000]

Antwort auf Beitrag Nr.: 36.750.100 von jensdab am 12.03.09 03:48:25

Ich finde es immer sehr lustig von den Börsenbriefen einen solchen Unsinn zu schreiben... Wenn die noch nicht einmal Unternehmungen unterscheiden können, welche auf dem Gebiet der adulten Stammzellen forschen und welche die auf den embryonalen Stammzellen...

Die embryonale Stammzellenforschung hat absolutes Nachholpotenzial, weil Bush hier strenge Restriktionen verabschiedete.

Wenn man in Stammzellenaktien investiert sein möchte, dann rate ich absolut zu GERON!
Allerdings kann dieses Investment auch schnell floppen, wenn es Probleme beim Test am Menschen gibt... Start wird im Sommer 2009 sein...

[sneake]

http://www.mffais.com/stem.html

[gerdass]

[gerdass]

Antwort auf Beitrag Nr.: 36.724.421 von TEDDYLOVE am 08.03.09 14:17:02

Noch sind sie günstig zu haben

[Frank012]

Nasdaq Biotechnology Index


http://data.cnbc.com/quotes/stem

hier das orderbuch
Symbol: stem eingeben
http://www.level2stockquotes.com/level-ii-quotes.html

[Frank012]

15.05.2009 15:05
U.S. Patent Office Upholds StemCells’ Patents - Company Moves to Resume Patent Infringement Cases Against Neuralstem
StemCells, Inc. (News) (NASDAQ:STEM) announced today that the U.S. Patent and Trademark Office (PTO) has upheld the validity of the remaining two neural stem cell patents which were subjected to reexamination proceedings commenced by Neuralstem, Inc. The upheld patents are the subject of two related lawsuits initiated by StemCells against Neuralstem, which allege infringement of a total of six patents. These six patents collectively claim the manufacture and use of human neural stem and progenitor cells as tools for drug discovery and as therapeutic agents. The PTO’s decision to uphold the two patents is final and cannot be appealed. Consequently, StemCells is asking the federal district court in Maryland to resume the infringement lawsuits against Neuralstem.

”The PTO’s latest action is a reaffirmation of the validity of the patents asserted against Neuralstem. Each of our reexamined patents has now been twice tested and twice granted by the Patent Office,” said Martin McGlynn, President and CEO of StemCells, Inc. ”We now look forward to our day in court. Litigation can be a slow and meticulous process, but we plan to ensure that those who wish to commercialize neural stem cells for drug discovery or therapeutic uses, recognize the validity and value of our patents.”

The two most recently upheld patents are U.S. Patent Number 6,294,346 and U.S. Patent Number 7,101,709, which claim, respectively, methods for using neural stem and progenitor cells for the screening of drugs and biological agents. In its latest communications, the PTO has issued Notices of Intent to Issue Ex Parte Reexamination Certificates for both the ‘346 and ‘709 patents. During the reexamination proceedings, the Company submitted minor amendments to certain, but not all, of the claims. With these notices of allowance, the PTO has affirmed all of the previously issued claims, as amended, and so all of the reexaminations initiated by Neuralstem have been resolved to StemCells' satisfaction. There are a total of 173 patent claims going forward from the six patents involved in the two suits against Neuralstem.

More About the Litigation Against Neuralstem

StemCells initiated its first lawsuit against Neuralstem in July 2006 in federal court in Maryland, alleging that Neuralstem’s activities violate claims in four patents exclusively licensed to StemCells. In late 2006, Neuralstem petitioned the PTO to reexamine two of the patents in the case, namely U.S. Patent No. 6,294,346 (claiming the use of human neural stem cells for drug screening) and U.S. Patent No. 7,101,709 (claiming the use of human neural stem cells for screening biological agents). Then, in April 2007, Neuralstem petitioned the PTO to reexamine the remaining two patents in the case, namely U.S. Patent No. 5,851,832 (claiming methods for proliferating human neural stem cells) and U.S. Patent No. 6,497,872 (claiming methods for transplanting human neural stem cells). In June 2007, the Company agreed to a voluntary stay of the first lawsuit while the reexamination proceedings were ongoing. In April 2008, the PTO reaffirmed the ’832 and ’872 patents.

In May 2008, StemCells filed a second patent infringement lawsuit in federal court in Northern California against both Neuralstem and its two founders, alleging that Neuralstem’s activities infringe claims in two additional patents exclusively licensed to the Company, specifically U.S. Patent No. 7,361,505 (claiming composition of matter of human neural stem cells derived from any source material) and U.S. Patent No. 7,115,418 (claiming methods for proliferating human neural stem cells). In addition, the second suit alleges various state law causes of action against Neuralstem arising out of its repeated derogatory statements to the public about our patent portfolio. In July 2008, the California court denied Neuralstem’s motion to dismiss the second lawsuit and then, in August 2008, it transferred the suit to Maryland for resolution.

About StemCells, Inc.

StemCells, Inc. is a clinical-stage biotechnology company focused on the research, development and commercialization of products derived from stem and progenitor cell technologies. In its therapeutic product development programs, StemCells is focused on developing cell-based therapeutics to treat diseases of the central nervous system and liver. StemCells has pioneered the discovery and development of HuCNS-SC® cells, its highly purified, expandable population of human neural stem cells. StemCells has completed a six patient Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL), a rare and fatal neurodegenerative disease that affects infants and young children. StemCells has also received approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial of the HuCNS-SC cells to treat Pelizaeus-Merzbacher Disease (PMD), a rare and fatal brain disorder that mainly affects young children. StemCells is also pursuing applications of its cell technologies to develop research tools, such as cell-based assays, media and reagent tools, which the Company believes represent nearer-term commercial opportunities. StemCells has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. Further information about StemCells is available on its web site at: www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (the ”Company”) and the validity, enforceability and value of the Company's patents. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainty regarding the validity and enforceability of our issued patents; litigation risks, including the risk that patents issued by the PTO may be held to be invalid or not infringed, and the high cost of patent litigation; risks as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in NCL, PMD or in future clinical trials of proposed therapies for other diseases or conditions despite the novel and unproven nature of the Company’s technologies; uncertainties about whether the Company will receive the necessary support of a clinical trial site and its institutional review board to initiate a clinical trial in PMD; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations, including such operations of the company for non-therapeutic applications, and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s manufacturing capabilities given its increasing preclinical and clinical commitments; and other factors that are described under the heading ”Risk Factors” in Item 1A of Part II of the Company’s Quarterly Report on Form 10-Q.



Contacts:

StemCells, Inc.
Rodney Young, 650-475-3100 Ext. 105
Chief Financial Officer
[e-mail]

[gerdass]

Antwort auf Beitrag Nr.: 37.154.956 von Frank012 am 12.05.09 15:24:57

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 37.050.101 von gerdass am 27.04.09 22:08:04

danke für deine einschätzung,
aber ich warte noch ein wenig und versuche bei 1,5 dollar zum zuge zu kommen.
gruß ted

[gerdass]

Antwort auf Beitrag Nr.: 37.190.969 von TEDDYLOVE am 16.05.09 13:26:24

ich drücke dir die Daumen

[gerdass]

[Frank012]

Nasdaq Biotechnology Index

[gerdass]

das schaut ja mal wieder vielversprechend aus

[gerdass]

Antwort auf Beitrag Nr.: 37.312.603 von Frank012 am 03.06.09 17:57:16

heuer wird hier was gehen können

[Frank012]

Antwort auf Beitrag Nr.: 37.343.828 von gerdass am 08.06.09 15:23:43

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 37.343.828 von gerdass am 08.06.09 15:23:43

sieht nicht mehr danach aus.
ich denke bis zum 19.6 sehen wir bestimmt meine 1,5 dollar

[gerdass]

Antwort auf Beitrag Nr.: 37.347.911 von TEDDYLOVE am 08.06.09 21:51:04

damit hätte ich eher kein Problem

[gerdass]

Antwort auf Beitrag Nr.: 37.190.969 von TEDDYLOVE am 16.05.09 13:26:24

du könntest recht haben

[gerdass]

.

[Frank012]

[gerdass]

Antwort auf Beitrag Nr.: 37.923.767 von Frank012 am 04.09.09 21:41:48

Steigerung

[gerdass]

Mal schauen, was heute hier geht

[Fruehrentner]

StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial

10 Feb 2010

Phase I Study Targets "Communication Highway" of the Brain in Children With PMD

PALO ALTO, CA, USA | February 10, 2010 | StemCells, Inc. (Nasdaq:STEM) announced today that its proprietary HuCNS-SC(R) human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that afflicts male children. The stem cells were administered yesterday at the University of California, San Francisco (UCSF) Children's Hospital by direct injection into the brain of a patient with connatal PMD, the most severe form of the disease. This marks the first time that neural stem cells have been transplanted as a potential treatment for a myelination disorder, and the second clinical trial involving the use of HuCNS-SC cells in a neurodegenerative disease.

Myelin is the substance that surrounds and insulates nerve cells' communications fibers (also known as axons). Without sufficient myelination, these fibers are unable to properly transmit nerve impulses, leading to a progressive loss of neurological function. Multiple sclerosis, transverse myelitis and certain types of cerebral palsy are more commonly known myelination disorders that also affect the central nervous system. Patients with PMD are born with a defective gene, which leads to insufficient myelin in the brain. Those with the most severe form of the disease, connatal PMD, lose the ability to walk and talk and eventually die, often before the age of 10. Currently, there are no effective treatments for PMD.

Stephen Huhn MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc., said, "The dosing of this first patient marks the beginning of a new chapter in the search for novel approaches to treat PMD and other myelination disorders. Cell therapy represents hope for those with diseases that small molecules and other biologics have been unable to address. Our ultimate goal in this clinical development program is to improve the outlook for these patients by establishing the basis for a safe and effective treatment option that could significantly slow or prevent the progression of the disease. While the primary focus in this first trial is safety, we will also be looking for evidence of new myelin formation in the patients' brains following the transplantation of our cells, as well as any signs of improved neurological function."

President and CEO Martin McGlynn stated, "We are extremely grateful to the family of this child, and to the clinicians and staff at UCSF, for bringing us one step closer to our goal of realizing a cell-based treatment for devastating myelination disorders that impact the central nervous system."

The trial is being directed by a team of prominent researchers at UCSF Children's Hospital, one of the leading medical centers in the United States for neonatology, pediatric neurology and neurosurgery. The principal investigator is David H. Rowitch, M.D., Ph.D., Chief of Neonatology at UCSF Children's Hospital, Professor of Pediatrics and Neurological Surgery, member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and a Howard Hughes Medical Institute investigator. The study co-investigators are Nalin Gupta, M.D., Ph.D., Chief of Pediatric Neurological Surgery, and Jonathan B. Strober, M.D., Director of Clinical Services for Child Neurology and Director of the Muscular Dystrophy Clinic at UCSF Children's Hospital.

About the PMD Clinical Trial

The Phase I trial is designed to assess the safety and preliminary effectiveness of HuCNS-SC cells as a potential treatment for PMD. The trial is expected to enroll four patients with connatal PMD. All patients will be transplanted with HuCNS-SC cells, and will be immunosuppressed for nine months. Following transplantation, the patients will be evaluated regularly over a 12-month period in order to monitor and evaluate the safety and tolerability of the HuCNS-SC cells, the surgery, and the immunosuppression. In addition, magnetic resonance imaging (MRI) of the brain post-transplant may enable the measurement of new myelin formation. As the Company intends to follow the effects of this therapy long-term, a separate four-year observational study will be initiated at the conclusion of this trial. Interested parties may find more information on patient enrollment at http://neonatology.ucsf.edu/nbri/pmd-trial/ or by visiting www.stemcellsinc.com. Additional information about this clinical trial can also be found at www.clinicaltrials.gov.

About HuCNS-SC Cells

StemCells' lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system. The transplanted cells are able to engraft, migrate, differentiate into neurons and glial cells, and possess the ability to survive for as long as one year with no sign of tumor formation or adverse effects. These findings show that HuCNS-SC cells, when transplanted, behave like normal stem cells, suggesting the possibility of a continual replenishment of normal human neural cells.

Preclinical studies performed by StemCells and its collaborators provide a rationale for potential therapeutic use of HuCNS-SC cells in myelination disorders. The Company has demonstrated that, when transplanted into an animal model of hypomyelination (shiverer mouse), HuCNS-SC cells engraft and differentiate into mature, specialized cells called oligodendrocytes, and form myelin sheaths around host nerve fibers. The initial myelination data in the shiverer mouse was published in the Proceedings of the National Academy of Science (Cummings, et al. 2005) and the results of additional myelination studies were presented at the International Society of Stem Cell Research (ISSCR) 2008 Annual Meeting in Philadelphia.

StemCells has completed a Phase I clinical trial of its HuCNS-SC cells for the treatment of Neuronal Ceroid Lipofuscinosis (NCL), a fatal brain disorder in children. Data from this trial demonstrated the clinical safety and tolerability of these cells. The Company's HuCNS-SC cells are also in preclinical development for other central nervous system disorders, including retinal degenerative diseases, such as age-related macular degeneration and retinitis pigmentosa, and spinal cord injury.

About UCSF

One of the nation's top children's hospitals, UCSF Children's Hospital creates an environment where children and their families find compassionate care at the healing edge of scientific discovery, with more than 150 experts in 50 medical specialties serving patients throughout Northern California and beyond. The hospital admits about 5,000 children each year, including 2,000 babies born in the hospital. Medi-Cal patients constitute more than half of the patient population.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

About StemCells, Inc.

StemCells, Inc. is focused on the development and commercialization of cell-based technologies. In its cellular medicine programs, StemCells is targeting diseases of the central nervous system and liver. StemCells' lead product candidate, HuCNS-SC cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the brand SC Proven(R), and is developing its cell-based technologies for use in drug screening and drug development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. Further information about StemCells is available at www.stemcellsinc.com.

SOURCE: StemCells, Inc.

[gerdass]

[gerdass]

STEMCELLS INC. voll im Trend.?

[Fruehrentner]

Bevor der thread hier historisch wird, hol ich ihn mal wieder hoch.

[gerdass]

Antwort auf Beitrag Nr.: 40.169.662 von Fruehrentner am 17.09.10 15:59:34

da waren aber noch ein paar Monate Luft

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 40.170.034 von gerdass am 17.09.10 16:39:34

hallo gerdass,
wollte mal reinschaun!
stem hat sich ja seit letztem jahr auf dem weg gemacht sein allzeittief zu testen.
es fehlen nur noch 11 us-cent, danach sollte es nochmals richtung norden gehen wenn obama sich für stammzellen forschung durchgesetzt hat!
ich werde mal bei 70 us-cent was einsammeln.
gruß teddylove

[EPB]

http://www.n-tv.de/wirtschaft/Obama-siegt-im-Stammzellenstre…

Mittwoch, 29. September 2010
US-Gericht hebt Förderungsstopp aufObama siegt im Stammzellenstreit
Die Stammzellenforschung in den USA darf nun doch staatlich gefördert werden. Ein Berufungsgericht hebt ein zwischenzeitlich erlassenes Förderungsverbot auf. US-Präsident Obama hatte im März 2009 verstärkte Forschungen auf diesem Gebiet angekündigt. Das wollten mehrere christliche Organisationen durch eine Klage verhindern.

Ein US-Berufungsgericht hat nun doch die staatliche Förderung der Stammzellenforschung erlaubt. Die Richter hoben damit ein in erster Instanz erlassenes Förderungsverbot auf. Gegen dieses Verbot war die US-Regierung in Berufung gegangen. Eine Begründung für seine Entscheidung gab das Berufungsgericht nicht.

US-Präsident Barack Obama hatte im März vergangenen Jahres den Kurs seines Vorgängers George W. Bush in dieser umstrittenen Frage korrigiert und angekündigt, dass die Forschung an embryonalen Stammzellen in den USA wieder mit staatlichen Mitteln unterstützt werden solle. Dagegen zog eine Klägergruppe um mehrere christliche Organisationen vor Gericht und erwirkte in erster Instanz per Eilentscheidung einen vorläufigen Förderstopp.
Chancen nutzen

Das Weiße Haus hatte gegen den Förderstopp Berufung eingelegt und argumentiert, dieser könne Millionen Schwerkranken oder Verletzten, die von der Forschung profitieren könnten, "irreparablen Schaden" zufügen. Forscher hoffen, dass embryonale Stammzellen in der Zukunft bei der medizinischen Behandlung schwerer Krankheiten möglicherweise als Ersatzmaterial dienen könnten.

Die Nutzung embryonaler Stammzellen ist ethisch stark umstritten, weil dazu Zellen aus Embryonen entnommen werden, die künstlich erzeugt wurden, dann aber keiner Frau eingepflanzt werden. Gegner der embryonalen Stammzellenforschung argumentieren, dass menschliches Leben bereits mit der Befruchtung der Eizelle beginne.

[gerdass]

http://de.advfn.com/p.php?pid=staticchart&s=N%5ESTEM&p=0&t=3…

[Fruehrentner]

StemCells, Inc. Advances to Second Clinical Trial in Batten Disease

28 Oct 2010

StemCells announced that it has initiated a second clinical trial of its HuCNS-SC(R) product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children

PALO ALTO, CA, USA | October 28, 2010 | StemCells, Inc. (Nasdaq: STEM - News) announced today that it has initiated a second clinical trial of its HuCNS-SC(R) product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children. The trial is designed to evaluate the safety and preliminary efficacy of the cells in patients with either infantile or late infantile NCL. The trial will enroll six patients with less advanced stages of the disease than those who participated in the Company's first NCL trial. Like the first NCL trial, this second trial is being conducted at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital, a leading medical center with nationally recognized programs in pediatric neurology and neurosurgery.

"The initiation of this trial represents a key advancement in the evaluation of our human neural stem cells as a potential therapeutic product," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "In this second trial, we will continue to assess safety, but will also look at certain measurements to evaluate the impact of these cells on disease progression. The trial is designed to enroll patients with less neuronal degeneration, which we believe will enhance the prospect of detecting clinical benefit. The data gathered from this trial will also help us begin to assess possible clinical endpoints for use in a pivotal clinical trial in NCL, and may provide important information about the potential for the use of these cells in other neurodegenerative disorders."

The trial is being led by Nathan Selden, MD, PhD, FACS, FAAP, Campagna Professor of Pediatric Neurosurgery and head of the Division of Pediatric Neurological Surgery at OHSU Doernbecher Children's Hospital and OHSU School of Medicine. Dr. Selden was co-principal investigator of the Company's first NCL trial.

"We are pleased to work with StemCells in the pursuit of an effective therapy for this devastating disease," stated Dr. Selden. "The first study conducted here at OHSU Doernbecher Children's Hospital revealed a favorable safety profile for human neural stem cell transplantation directly into the brain. This second trial is an important next step, and may allow us to see evidence of clinical efficacy from the transplanted cells. We look forward to further evaluating the potential of these cells to truly help children facing a desperate illness."

About the Phase Ib NCL Trial

The Phase Ib trial is designed to further assess the safety and preliminary efficacy of HuCNS-SC cells as a potential treatment for NCL. All patients will be transplanted with HuCNS-SC cells via a neurosurgical procedure, and will be immunosuppressed for nine months. Following transplantation, the patients will be evaluated regularly over a 12-month period in order to monitor and evaluate the safety and tolerability of the HuCNS-SC cells, the surgery, and the immunosuppression. In addition, MRI evaluations will focus on potential measures of effect from the donor cells, including assessing and tracking cerebral volume and unique neuronal metabolites, both of which are negatively impacted by disease progression. As the Company intends to follow the effects of this therapy long-term, a separate four-year observational study will be initiated at the conclusion of this trial. For information on patient enrollment, interested parties may call [phone]. Additional information about this clinical trial can also be found at www.stemcellsinc.com and www.clinicaltrials.gov.

About Neuronal Ceroid Lipofuscinosis (Batten Disease)

Neuronal ceroid lipofuscinosis (NCL) is a fatal lysosomal disorder that afflicts infants and young children. The disorder, often referred to as Batten disease, is caused by genetic mutations, and children who inherit the defective gene are unable to produce enough of an enzyme that processes cellular waste substances that accumulate in a part of cells known as the lysosome. Without the enzyme, the cellular waste builds up, and eventually the cells cannot function and die. Children with NCL appear healthy when born, but as their brain cells die, they begin to suffer seizures and progressively lose motor skills, sight and mental capacity. Eventually, they become blind, bedridden and unable to communicate or function independently. There currently is no effective treatment for the disease. The infantile and late infantile forms of NCL are caused by different genetic mutations. As the names imply, the two forms begin to afflict patients at different stages of infancy, but both have similar disease progression and outcomes.

StemCells has shown in preclinical studies that its HuCNS-SC cells produce the enzyme missing in NCL and protect neurological function. The Company's clinical development strategy in NCL may also provide important information on the applicability of HuCNS-SC cells for other lysosomal storage disorders that affect the central nervous system, as well as for a broad range of other neurological diseases.

About HuCNS-SC Cells

StemCells' lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system. The transplanted cells are able to engraft, migrate, differentiate into neurons and glial cells, and possess the ability to survive long term with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, this suggests the possibility of a durable clinical effect following a single transplantation.

StemCells has completed a Phase I clinical trial of its HuCNS-SC cells for the treatment of NCL. Data from this trial demonstrated the clinical safety and tolerability of these cells. The Company continues to follow patients who completed this trial, some of whom are two to three years post-transplant. In addition to its clinical development in NCL, StemCells is currently conducting a Phase I trial of HuCNS-SC cells as a potential treatment for Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder in children. HuCNS-SC cells are also in preclinical development for other central nervous system disorders, including spinal cord injury and age-related macular degeneration. The Company is working toward initiating clinical trials in both of these conditions in 2011 and 2012, respectively.

About OHSU Doernbecher Children's Hospital

OHSU Doernbecher Children's Hospital is a world-class facility that each year cares for tens of thousands of children from Oregon, southwest Washington and around the nation, including national and international referrals for specialty care. Children have access to a full range of pediatric care, not just treatments for serious illness or injury, resulting in more than 147,000 outpatient visits, discharges, surgeries and pediatric transports annually. In addition, nationally recognized physicians ensure that children receive exceptional care at OHSU Doernbecher, including outstanding cancer treatment, specialized neurology care and highly sophisticated heart surgery in the most patient- and family-centered environment. Pediatric experts from OHSU Doernbecher travel throughout Oregon and southwest Washington to provide specialty care to some 3,000 children at more than 150 outreach clinics in 13 locations.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells' lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R)brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at www.stemcellsinc.com.

SOURCE: StemCells, Inc.

[TEDDYLOVE]

hallo da draußen,
hier geht in den letzten tagen die post ab und keiner schreibt mehr was dazu.
die zielkurse sind bei yahoo,finance mit 2,60 dollar angegeben, das sind mehr als 100 prozent das ist doch was.
gruß
teddylove

[gerdass]

Antwort auf Beitrag Nr.: 40.540.882 von TEDDYLOVE am 17.11.10 19:30:01

das geht so manch einem nicht schnell genug
es reicht, wenn wir zwei hier was verdienen

[TEDDYLOVE]

Antwort auf Beitrag Nr.: 40.541.644 von gerdass am 17.11.10 21:03:53

hallo,
war gestern schon ein guter tag aber eine korrektur sollte heute angesagt sein.
das überschreiten der 1 dollarbarriere sieht positiv aus und gibt anlass zum hoffen.
gruß ted

[bua321]

gerdass:

wir sind zu dritt !
bin schon lange dabei und wieder im Plus !


STEM performed gerade nett und keiner bekommt es hier mit.
die Masse möge diesen Wert bei 10,- € aufwärts entdecken.

gelle !

[gerdass]

[Fruehrentner]

StemCells, Inc. Completes Dosing in Second Trial of HuCNS-SC(R) Neural Stem Cells

17 Feb 2011

StemCells announced that the fourth and final patient in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) has been transplanted with the Company's HuCNS-SC(R) cells (purified human neural stem cells).

PALO ALTO, CA, USA I February 17, 2011 I StemCells, Inc. (Nasdaq:STEM) today announced that the fourth and final patient in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) has been transplanted with the Company's HuCNS-SC(R) cells (purified human neural stem cells). PMD is a fatal myelination disorder that afflicts male children. This clinical trial, which is being conducted in collaboration with UCSF Benioff Children's Hospital, is the first to evaluate neural stem cells as a potential treatment for a myelination disorder. Results of the trial will be reported in early 2012.

Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program, said, "Completing enrollment in our second clinical trial of HuCNS-SC cells brings us one step closer to understanding how our cell might offer clinical benefit for patients with serious neurological conditions like PMD. We deeply appreciate the participation of the patients and their families in this important clinical research, and are grateful to the expert team of investigators at UCSF for helping us to advance the potential for neural stem cell therapy.

"Between the Phase I Batten trial completed in 2009 and the PMD trial, we have dosed a total of 10 patients. Both of these trials involved the transplantation of HuCNS-SC cells directly into the brain at very high dose levels. The demonstrated feasibility of administering a significant cell dose to multiple regions of the brain in a single surgery may be relevant to the treatment of other neurodegenerative disorders."



About the PMD Trial

The Phase I trial is designed to assess the safety and preliminary efficacy of HuCNS-SC cells when transplanted in four patients with connatal PMD, the most severe form of the disease. Under the trial protocol, each patient will be evaluated regularly over a 12-month period following transplantation in order to monitor and evaluate the safety and tolerability of the HuCNS-SC cells, the surgery, and nine months of immunosuppression. In addition, magnetic resonance imaging (MRI) of the brain post-transplant may enable the measurement of new myelin formation. As the Company intends to follow the effects of this therapy long-term, a separate four-year observational study will be initiated upon completion of this trial. Additional information about this clinical trial can be found at http://neonatology.ucsf.edu/nbri/pmd-trial/ or by visiting www.stemcellsinc.com or www.clinicaltrials.gov.

About PMD

Patients with PMD are born with a defective gene, which leads to insufficient myelin in the brain. Myelin is the substance that surrounds and insulates nerve cells' communications fibers (also known as axons). Without sufficient myelination, these fibers are unable to properly transmit nerve impulses, leading to a progressive loss of neurological function. Those with the most severe form of the disease, connatal PMD, lose the ability to walk and talk and eventually die, often before the age of 10. Currently, there are no effective treatments for PMD.

About HuCNS-SC Cells

StemCells' lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, this suggests the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing studies of these cells in two fatal brain disorders in children.

Preclinical studies performed by StemCells and its collaborators provide a rationale for potential therapeutic use of HuCNS-SC cells in myelination disorders. The Company has demonstrated that, when transplanted into an animal model of hypomyelination (shiverer mouse), HuCNS-SC cells engraft and differentiate into mature, specialized cells called oligodendrocytes, and form myelin sheaths around host nerve fibers.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting disorders of the central nervous system and the liver. StemCells' lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in clinical development for spinal cord injury and two fatal neurodegenerative disorders in children, and in preclinical development for retinal disorders such as age-related macular degeneration. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

[Fruehrentner]

StemCells, Inc. Discontinues Batten Disease Program
08 Apr 2011

StemCells announced that it has discontinued its Phase Ib clinical trial in neuronal ceroid lipofuscinosis (NCL, also referred to as Batten disease) due to lack of patient accrual

PALO ALTO, CA, USA | April 8, 2011 | StemCells, Inc. (Nasdaq: STEM - News) today announced that it has discontinued its Phase Ib clinical trial in neuronal ceroid lipofuscinosis (NCL, also referred to as Batten disease), a rare and fatal neurodegenerative disorder in children, due to lack of patient accrual. In 2009, the Company completed a Phase I safety trial of its HuCNS-SC(R) human neural stem cells in six patients with advanced stages of NCL at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital. In October 2010, the Company initiated a Phase Ib trial at OHSU to evaluate the cells in an additional six patients in earlier stages of the disease, and therefore most likely to benefit from a timely neural stem cell transplant. However, no eligible patients have been identified or enrolled despite diligent efforts by the clinical investigators over the past six months.

Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc., stated, "In clinical trials for rare diseases, timely patient enrollment is always of concern to study sponsors. Unfortunately, this concern has materialized in our Phase Ib NCL study. Out of 22 initial prospects, not one patient has met the entry criteria. This experience has also highlighted the significant challenges the Company would face in completing, within a reasonable period of time, the much larger studies in the target patient population that would ultimately be required for marketing approval. These factors, combined with our limited corporate resources, have prompted the decision to shelve our clinical development program in NCL at this time."

Martin McGlynn, President and CEO of StemCells, Inc., commented, "We wish to thank the clinicians and staff at OHSU for their dedication and contributions to this pioneering stem cell research. We are also deeply grateful to the families of the six patients involved in our Phase I trial. No doubt, this decision will come as a great disappointment to the NCL community, but I would like to point out that their support has greatly contributed to the prospect that this groundbreaking technology will one day result in a treatment for a broad range of debilitating neurodegenerative disorders. As a result of this clinical research, we have established that we can safety transplant meaningful doses of HuCNS-SC cells directly into the brain, and that patients can tolerate both the surgical intervention and the immunosuppression regimen. We also now have evidence that, once transplanted, the cells are capable of engrafting and surviving long-term, suggesting the possibility of durable clinical benefit. And, importantly, we have not observed any evidence of aberrant cell behavior or tumor formation in patients who are now more than three years post-transplant, and whom we continue to follow as part of a long-term observational study."

[Fruehrentner]

StemCells, Inc. Advances Alzheimer's Disease Program Through Collaboration With Leading Researcher

18 Apr 2011

StemCells announced that it has entered into a collaboration with Frank LaFerla, Ph.D to study the therapeutic potential of the Company's HuCNS-SC(R) human neural stem cells in Alzheimer's disease

PALO ALTO, CA, USA | April 18, 2011 | StemCells, Inc. (Nasdaq:STEM - News) announced today that it has entered into a collaboration with Frank LaFerla, Ph.D., a world renowned leader in Alzheimer's disease research, to study the therapeutic potential of the Company's HuCNS-SC(R) human neural stem cells in Alzheimer's disease. Dr. LaFerla's published research has shown that mouse neural stem cells enhance memory in a mouse model of Alzheimer's disease. The goal of this collaboration is to replicate these results using the Company's human neural stem cells.

"This collaboration is a natural evolution of Dr. LaFerla's pioneering research, and will build on the promising results we have seen to date in other preclinical studies of our cells in Alzheimer's disease," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Our growing human clinical database already includes a favorable safety profile in fatal neurodegenerative disorders as well as proof of engraftment of our HuCNS-SC cells in the brain. Consequently, we will be well positioned for rapid advancement into clinical testing in Alzheimer's disease following successful results from this research collaboration."

Dr. LaFerla, Director of the University of California, Irvine (UCI) Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Chancellor's Professor, Neurobiology and Behavior in the School of Biological Sciences at UCI, stated, "Novel treatment approaches for Alzheimer's disease are urgently needed. From what we have seen to date, we believe that neural stem cells may hold the key to impacting the course of this debilitating disease, and we look forward to working with StemCells to explore this exciting prospect."

Research conducted to date provides a strong rationale for the use of neural stem cells as a potential treatment for Alzheimer's disease. In addition to Dr. LaFerla's groundbreaking research with mouse neural stem cells, which was published in August 2009 in the Proceedings of the National Academy of Sciences (PNAS), StemCells has separately conducted studies of its HuCNS-SC cells in another Alzheimer's model as part of a previous collaboration with George Carlson, Ph.D. at the McLaughlin Research Institute. This research, which was funded by a National Institutes of Health (NIH) Small Business Technology Transfer grant, demonstrated that StemCells' HuCNS-SC cells are capable of surviving in the hostile environment reflective of an Alzheimer's brain, which characteristically features abnormal accumulations of brain lesions called plaques and tangles that contribute to loss of function in healthy neurons.

[Fruehrentner]

StemCells, Inc. to Present Clinical Evidence of Long-Term Survival of HuCNS-SC(R) Cells Following Completion of Immunosuppression Regimen

15 Jun 2011

StemCells announced that it will present evidence of engraftment, migration and the long-term survival of its proprietary HuCNS-SC neural stem cells following transplantation into patients with a severe neurological disorder

PALO ALTO, CA, USA | June 15, 2011 | StemCells, Inc. (Nasdaq:STEM - News) announced today that it will present evidence of engraftment, migration and the long-term survival of its proprietary HuCNS-SC neural stem cells following transplantation into patients with a severe neurological disorder. Importantly, the results show that the cells can persist following the completion of the planned year-long immunosuppression regimen. The data, which supports the Company's premise regarding the viability and utility of neural stem cell therapy as a potential treatment for a wide range of debilitating and lethal central nervous system (CNS) disorders, will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario, by Nobuko Uchida, Vice President, Stem Cell Biology at StemCells, Inc.

"These findings support our vision of a one-time transplantation of stem cells with a lasting clinical benefit," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "In a field of promises, we now have confirmation that we are on the right path. Ultimately, we hope to show that our HuCNS-SC human neural stem cells can dramatically impact a broad spectrum of neurological disorders."

The durability of the Company's HuCNS-SC human neural stem cells within the hostile inflammatory environment of the diseased brain is only one important aspect of the results being presented. The authors also report the persistence of the transplanted donor cells long after immunosuppressive treatment has been discontinued. This finding is significant because other allogeneic tissue and organ transplants usually require life-long immunosuppression, which carries increased risk for cancer and opportunistic infections. The data to be presented by StemCells, Inc. also support the belief that the central nervous system is "immune-privileged" and that a relatively brief period of immunosuppression may be all that is required to avoid the risk of transplant rejection within the CNS. Additional studies will determine whether immunosuppression protocols can be further optimized.

The data to be presented was derived from postmortem examinations of three patients in the Company's Phase I clinical trial of HuCNS-SC cells in neuronal ceroid lipofuscinosis (NCL, also referred to as Batten disease), a rare and fatal neurodegenerative disorder in children. The patients expired from causes related to the underlying disease. Analysis of the brain tissue of two of the patients at autopsy revealed the presence of the donor cells at the sites of transplantation as well as evidence of migration into deeper structures of the brain, confirming similar observations made in animal models. In one of these patients, the persistence of the donor cells was evident 2.5 years post transplant and 1.5 years after completion of the immunosuppression regimen.

###


About ISSCR

The International Society for Stem Cell Research (ISSCR) is an independent, nonprofit organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application. The ISSCR Annual Meeting is the preeminent meeting of stem cell experts from public, private, academic, and government institutions from around the world, and provides a forum which features the leading research and discoveries of the year.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to file an IND by year-end 2011 to initiate a clinical trial of HuCNS-SC cells in age-related macular degeneration, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease and stroke. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

SOURCE: The StemCells, Inc.

[CowNChicken]

Weiß jemand von euch, was in unseren einstigen Lieblingen Stemcells und Aastrom vorgeht? Was treiben die die ganze Zeit? Gibt es Fortschritte? Haben die schon irgendwas zugekleistert mit ihren Stammzellen?

Wie ist die finanzielle Lage in den Unternehmen, wie lange halten sie finanziell noch durch?

Danke für die zahlreichen Antworten!

LG,
Cow

[Fruehrentner]

StemCells, Inc. Announces World's First Neural Stem Cell Transplant in Spinal Cord Injury Patient

22 Sep 2011

StemCells announced that the first patient in the Company's breakthrough Phase I/II clinical trial in chronic spinal cord injury was successfully transplanted with the Company's proprietary HuCNS-SC(R) adult neural stem cells

NEWARK, CA, USA | September 22, 2011 | StemCells, Inc. (Nasdaq: STEM) announced today that the first patient in the Company's breakthrough Phase I/II clinical trial in chronic spinal cord injury was successfully transplanted with the Company's proprietary HuCNS-SC(R) adult neural stem cells. The stem cells were administered yesterday at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation. The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman, a visiting staff neurosurgeon also on faculty at Department of Neurosurgery, Stanford University, and Dr. K. Min, an orthopedic surgeon at Balgrist University Hospital.

"I am pleased to be a part of this innovative clinical trial designed to help us assess the safety and potential efficacy of HuCNS-SC stem cells for spinal cord injury," explains Dr. Armin Curt, Principal Investigator. "The preclinical data underlying this trial provided compelling rationale to conduct a study of this nature in spinal cord-injured patients." StemCells, Inc. has published numerous preclinical studies demonstrating the therapeutic potential of the Company's human neural stem cells for the treatment of acute and chronic spinal cord injury. These studies were conducted in close collaboration with Drs. Aileen Anderson and Brian Cummings of the University of California, Irvine.

The first patient transplanted in the trial, a 23-year-old German man, suffered a spinal cord injury in an automobile accident in April of this year. He sustained a complete loss of sensation and mobility from the waist down. When asked about his decision to enroll in this leading-edge study, he said: "This terrible injury crossed out almost all my life plans, and has led me to an unexpected path. Participating in this clinical trial not only gives me a sense of hope, but it also helps move this important research forward."

"With this first patient enrolled and dosed, we remain on track to meet our goal of treating the first cohort of patients by the end of this year," said Stephen Huhn MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "While the trial's first cohort will consist of patients with the most severe, complete injury, the second and third cohorts will progress to patients with less severe, incomplete injury. This unique trial design will allow us to evaluate the potential of our HuCNS-SC cells as a treatment for a broad spectrum of spinal cord injury patients. Even a small improvement could have a marked impact on quality of life for the millions of people who suffer from this debilitating condition."

About the Clinical Trial

The Phase I/II clinical trial of StemCells, Inc.'s HuCNS-SC purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment. The first three patients will all have injuries classified as ASIA A, in which there is no apparent neurological function below the injury level, the most severe level identified by the American Spinal Injury Association (ASIA) Impairment Scale. The second and third cohorts will be patients classified as ASIA B and ASIA C, those with less severe injury, in which there is some preservation of sensory or motor function. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor and bowel/bladder function.

All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and a separate 4-year observational study will be initiated at the conclusion of this trial.

For information on patient enrollment, interested parties may contact the study nurse either by phone at [phone], or by email at [e-mail].

Additional information about the Company's spinal cord injury program can be found on the StemCells, Inc. website at http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Tr… and at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord… including video interviews with Company executives and independent collaborators.

About Chronic Spinal Cord Injury

According to a study reported by the Christopher and Dana Reeve Foundation, nearly 1.3 million people in the United States are estimated to be living with chronic spinal cord injury. The chronic phase of spinal cord injury is considered to begin when inflammation has stabilized and recovery has reached a plateau, which is typically several months following injury. Currently, there are no effective treatment options for patients with chronic spinal cord injury, and treatment approaches have generally targeted the acute and sub-acute time points, which are within hours or days of injury. Given the unmet need in chronic spinal cord injury, restoring some degree of function for patients at time points beyond the acute phase could have a transformative impact on the field. StemCells hopes to address a broad population of spinal cord-injured patients by opening the window of opportunity for therapeutic intervention well after the acute injury and targeting a wide range of injury levels and degrees of impairment.

About Balgrist University Hospital

Balgrist University Hospital, University of Zurich is recognized worldwide as a highly specialized center of excellence providing examination, treatment and rehabilitation opportunities to patients with serious musculoskeletal conditions. The clinic owes its leading international reputation to its unique combination of specialized medical services. The hospital's carefully-balanced, interdisciplinary network brings together under one roof medical specialties including orthopedics, paraplegiology, radiology, anesthesiology, rheumatology, and physical medicine. More information about Balgrist University Hospital is available at www.balgrist.ch.

[CowNChicken]

Sagt mal, was hat Aastrom eigentlich, was Stemcells nicht hat?
Könnt ihr mir erklären, wie die riesigen Kursunterschiede zustande kommen?
Aktiensplits, mehr Investitionen bei Aastrom, bessere klinische Ergebnisse bei Aastrom?

Danke!
Cow

[gony2]

was ist mit stemcells pasiert? delisted in d?

[Fruehrentner]

StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial

02 Feb 2012

NEWARK, CA, USA I February 2, 2012 I StemCells, Inc. (Nasdaq:STEM - News) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD.

"With the approval of this trial, we have accomplished something truly unique in the stem cell field, which is the extension of clinical testing of our proprietary human neural stem cell platform to all three elements of the central nervous system: the brain, spinal cord and eye," said Martin McGlynn, President and CEO of StemCells, Inc. "The preclinical data supporting our IND is particularly compelling and we look forward to getting this trial underway."

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina. Patients' vision will be evaluated using conventional methods of ophthalmological assessment at predetermined intervals over a one-year period. Patients will then be followed for an additional four years in a separate observational study.

Preclinical data submitted as part of the Company's Investigative New Drug application demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in a well-established animal model of retinal disease that is relevant to dry AMD. HuCNS-SC transplants significantly protect against the degeneration of photoreceptors, the key cells of the eye involved in vision. Moreover, the number of cone photoreceptors, which are responsible for central vision, remain constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed. In humans, degeneration of the cone photoreceptors account for the unique pattern of visual loss in dry AMD. A summary of the Company's preclinical data was published in the February issue of the international peer-reviewed European Journal of Neuroscience, and is available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.…

"We have published the preclinical evidence demonstrating that our human neural stem cells might offer a safe, effective and simple approach to treating AMD and other retinal diseases," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Our approach is to provide durable protection of photoreceptors, thereby preserving vision, as opposed to approaches that aim to replace photoreceptors or the retinal pigmented epithelial cells. Furthermore, our preclinical data supports our hypothesis that we can achieve clinical benefit with a single transplant in AMD patients."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, and the Company expects to initiate a Phase I/II clinical trial in dry AMD in the near future. In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

SOURCE: StemCells

[Fruehrentner]

StemCells, Inc's Milestone Clinical Trial in Pelizaeus-Merzbacher Disease Shows Evidence of Myelination Following Human Neural Stem Cell Rransplantation

02 Apr 2012


- Trial Provides Proof-of-Concept for Cell-Based Therapy in a Myelination Disorder

- Company to Host Conference Call Today to Discuss Summary Results

NEWARK, CA, USA I April 2, 2012 I StemCells, Inc. (Nasdaq: STEM) today announced preliminary evidence of progressive and durable donor-cell derived myelination in all four patients who underwent transplantation with the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) in its clinical trial for Pelizaeus-Merzbacher disease (PMD), a rare hypo-myelination disorder in children. In addition, clinical assessment revealed small but measureable gains in motor and/or cognitive function in three of the four patients; the fourth patient remained clinically stable. The study was conducted by researchers at the University of California, San Francisco (UCSF).

A summary of the trial results were presented Saturday, March 31, at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. The findings are being submitted for publication in a peer-reviewed scientific journal.

"The results from this Phase I study are meaningful and important," said study investigator Nalin Gupta, MD, PhD, UCSF associate professor of neurological surgery and pediatrics and chief of pediatric neurological surgery at UCSF Benioff Children's Hospital. "The safety and clinical outcomes a year after transplantation in this Phase I study, combined with durable radiological signals of myelin formation, provide objective evidence of a biological effect of HuCNS-SC transplantation that addresses the fundamental basis of the pathology in the brain of PMD patients. We also wish to recognize the families' contribution to this study. These advances would not be possible without their willingness to participate in this clinical research."

Patients with PMD have a defective gene, which leads to insufficient myelin in the brain. The disease occurs only in males, and those with the most severe form of the disease, connatal PMD, are significantly disabled from birth and usually die, within the first decade of life. The study was the first to test transplantation of neural stem cells as a potential treatment for a myelination disorder. Myelin is the substance that surrounds and insulates nerve cells' communications fibers (also known as axons). Without sufficient myelination, these fibers are unable to properly transmit nerve impulses, leading to a progressive loss of neurological function, and death.

The open-label Phase I trial, conducted between February 2010 and February 2012, enrolled four patients with the connatal form of PMD, between the ages of 14 months and 5 years, and was designed to assess safety and preliminary efficacy of the intervention. The study used magnetic resonance (MR) imaging, commonly employed in other neurological diseases, to explore signs of myelination related to the transplanted neural stem cells. The HuCNS-SC transplants were surgically delivered to multiple sites within the frontal lobes of the brain. Patients also received immunosuppression for nine months following transplantation and underwent intensive follow-up neurological assessments and MR imaging for twelve months following transplantation. A separate four-year observational study will continue to monitor and report the future progress for all four patients.

At the one-year interval, MR imaging showed changes compatible with increased myelination in the region of the transplantation. The MR signs of myelination persisted after the withdrawal of immunosuppression at nine months and were also found to progress over time. The development of new myelin signals is unprecedented in patients with connatal PMD and is consistent with HuCNS-SC engraftment.

"The finding of myelin formation in this first exploratory study is indeed very encouraging," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "We believe that the results of this trial provide proof-of-concept and a compelling rationale for the Company to begin planning for a controlled Phase II study in PMD. These results may also have implications for other leukodystrophies, as well as more common myelin disorders including transverse myelitis, multiple sclerosis and periventricular white matter injury seen in Cerebral Palsy. We are very pleased to be working with investigators at UCSF and deeply appreciate the critical research expertise they have dedicated to the trial."

[CowNChicken]

Die Aktie notiert derzeit nur noch doppelt so hoch wie der Buchwert, der bei ca. 0,5 Dollar je Aktie liegt.
Ist das historisch gesehen nicht ausgesprochen niedrig bewertet? So wenn man noch an einen Durchbruch in der Stammzellenforschung glaubt.

VG

[Fruehrentner]

Bedeutende News aus der Stammzelltherapiebranche!!



World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal

18 May 2012

Historic decision offers hope to children suffering from life-threatening GvHD

COLUMBIA, MD, USA I May 17, 2012 I Osiris Therapeutics Inc. (NASDAQ: OSIR - News) announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. The historic decision marks the world’s first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD — a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis.

"I am very proud of the leadership role Canada has taken in advancing stem cell therapy and particularly gratified that this historic decision benefits children who would otherwise have little hope," said Andrew Daly, M.D., Clinical Associate Professor, Department of Medicine and Oncology at the University of Calgary, Canada and Principal Investigator in the phase 3 clinical program for Prochymal. "As a result of Health Canada's comprehensive review, physicians now have an off-the-shelf stem cell therapy in their arsenal to fight GvHD. Much like the introduction of antibiotics in the late 1920's, with stem cells we have now officially taken the first step into this new paradigm of medicine."

Prochymal was authorized under Health Canada's Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing.

“Today is not only a great day for Osiris, but for everyone involved in the responsible development of stem cell therapies,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. “Most importantly, today is a great day for children and their families who bravely face this horrific disease. While today marks the first approval of a stem cell drug, now that the door has been opened, it will surely not be the last.”

Health Canada’s authorization was made following the recommendation of an independent expert advisory panel, commissioned to evaluate Prochymal's safety and efficacy. In Canada, Prochymal is now authorized for the management of acute GvHD in children who fail to respond to steroids. The approval was based on the results from clinical studies evaluating Prochymal in patients with severe refractory acute GvHD. Prochymal demonstrated a clinically meaningful response at 28 days post initiation of therapy in 61-64 percent of patients treated. Furthermore, treatment with Prochymal resulted in a statistically significant improvement in survival when compared to a historical control population of pediatric patients with refractory GvHD (p=0.028). The survival benefit was most pronounced in patients with the most severe forms of GvHD. As a condition of approval, the clinical benefit of Prochymal will be further evaluated in a case matched confirmatory trial and all patients receiving Prochymal will be encouraged to participate in a registry that will monitor the long-term effects of the therapy.

“Refractory GvHD is not just deadly to the patients it afflicts, but is devastating for the family, friends, and caregivers who watch helplessly as the disease progresses,” said Joanne Kurtzberg, MD, Head of the Pediatric Bone Marrow Transplant Program at Duke University and Lead Investigator for Prochymal. "I have personally seen Prochymal reverse the debilitating effects of severe GvHD in many of my patients and now, after nearly two decades of research, the data demonstrating consistently high response rates, a strong safety profile and improved survival clearly support the use of Prochymal in the management of refractory GvHD."

Prochymal is currently available in several countries, including the United States, under an Expanded Access Program (EAP). Prochymal will be commercially available in Canada later this year.

“Today Osiris turns the promise of stem cell research into reality, delivering on decades of medical and scientific research,” said Peter Friedli, Chairman and Co-founder of Osiris. “It took 20 years of hard work and perseverance and I want to personally thank everyone involved for their dedication to this important mission.”

In addition to the extensive intellectual property protection Osiris has around Prochymal, which includes 48 issued patents, Health Canada's decision will also provide Prochymal with regulatory exclusivity within the territory. Canada affords eight years of exclusivity to Innovative Drugs such as Prochymal, and an additional six-month extension is available since it addresses a pediatric population.

Webcast and Conference Call

A webcast and conference call is scheduled for tomorrow, May 18, 2012 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing [phone] (U.S. participants) or [phone] (international participants).

A replay of the conference call will be available approximately two hours after the completion of the call through May 24, 2012. Callers can access the replay by dialing [phone] (U.S. participants) or [phone] (international participants). The audio replay confirmation code is 82905846. To access a replay of the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm.

About GvHD

GvHD represents a major unmet medical need with no approved treatment until Prochymal. GvHD is the leading cause of transplant related mortality, in which immune cells contained within the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. Severe GvHD can cause blistering of the skin, intestinal hemorrhage and liver failure. Severe GvHD is extremely painful and fatal in up to 80 percent of cases. Currently, steroids are used as first-line therapy with a success rate of only 30-50 percent. When steroids fail, treatment options are limited to immunosuppressive agents used off-label with little benefit and significant toxicities.

About Prochymal (remestemcel-L)

Prochymal is the world’s first approved drug which has a stem cell as its active ingredient. Developed by Osiris Therapeutics, Prochymal is an intravenous formulation of mesenchymal stem cells (MSCs), which are derived from the bone marrow of healthy adult donors between the ages of 18 and 30 years. The MSCs are selected from the bone marrow and grown in culture so that up to 10,000 doses of Prochymal can be produced from a single donor. Prochymal is truly an off-the-shelf stem cell product that is stored frozen at the point-of-care and infused through a simple intravenous line without the need to type or immunosuppress the recipient. Prochymal is currently approved in Canada for the management of acute graft-versus-host disease (GvHD) in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program. Prochymal is currently in Phase 3 trials for refractory Crohn’s disease and also being evaluated in clinical trials for the treatment of myocardial infarction (heart attack) and type 1 diabetes.

About Notice of Compliance with Conditions

An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. Products approved under Health Canada’s NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. Such products have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to such products on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading stem cell company, having developed the world’s first approved stem cell drug, Prochymal. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic areas and wound healing areas. Osiris currently markets Prochymal for refractory GvHD, Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. The company’s pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign patents.

SOURCE: Osiris Therapeutics

[Fruehrentner]

von Stemcells Inc. gibt's ebenfalls news:



StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial

17 May 2012

Trial Proceeding to Enroll Patients With Incomplete Injury

NEWARK, CA, USA I May 17, 2012 I StemCells, Inc. (Nasdaq: STEM) today announced completion of the first planned interim safety review of the Company's Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® cells (purified human neural stem cells), represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury. A summary of the data will be presented by Armin Curt, M.D., principal investigator for the clinical trial, at the Interdependence 2012 Global SCI Conference, which is being held in Vancouver, British Columbia, from May 15 to 17, 2012.

The interim data is from the first cohort of patients, all of whom suffered a complete spinal cord injury in which there is no neurological function below the level of the injury. All patients enrolled were transplanted with a dose of 20 million cells at the site of injury in the thoracic spinal cord. There were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first four months following transplantation of the cells. The data from multiple evaluations of the patients during this four month period have been reviewed by an independent Data Safety Monitoring Committee, which has recommended that the study advance to enrollment of patients with incomplete neurological injury. Enrollment is now underway and is open to patients in Europe, the United States and Canada with incomplete spinal cord injury. The trial, which is being conducted at Balgrist University Hospital, Zurich, Switzerland, is the only ongoing clinical trial evaluating neural stem cell transplantation in spinal cord injury.

"We are very encouraged by the interim safety outcomes for the first cohort," said Dr. Curt, who is Professor and Chairman of the Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at Balgrist University Hospital. "The patients in the trial are being closely monitored and undergo frequent clinical examinations, radiological assessments by MRI and sophisticated electrophysiology testing of spinal cord function. The comprehensive battery of tests provides important safety data and is very reassuring as we progress to the next stage of the trial."

The Interdependence 2012 Global SCI Conference is intended to bring together international healthcare and research facilities to showcase their work through presentations, workshops and exhibits and to discuss how to advance research, implement new best practices and shape the next generation of spinal cord injury research. Interdependence 2012 is jointly organized by the Rick Hansen Institute, a Canadian not-for-profit organization committed to accelerating the translation of discoveries and best practices into improved treatments for people with spinal cord injuries, and the Rick Hansen Foundation.

About the Spinal Cord Injury Clinical Trial

The Phase I/II clinical trial of StemCells, Inc.'s HuCNS-SC® purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment. The Company has dosed the first three patients all of whom have injuries classified as AIS A, in which there is no neurological function below the injury level. The second and third cohorts will be patients classified as AIS B and AIS C, those with less severe injury, in which there is some preservation of sensory or motor function. The injuries are classified according to the American Spinal Injury Association Impairment Scale (AIS). In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor and bowel/bladder function.

All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and a separate four-year observational study will be initiated at the conclusion of this trial.

The trial is being conducted at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation, and is open for enrollment to patients in Europe, Canada and the United States. If you believe you may qualify and are interested in participating in the study, please contact the study nurse either by phone at [phone] or by email at [e-mail].

Additional information about the Company's spinal cord injury program can be found on the StemCells, Inc. website at http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Tr… and at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord… including video interviews with Company executives and independent collaborators.

About Balgrist University Hospital

Balgrist University Hospital, University of Zurich is recognized worldwide as a highly specialized center of excellence providing examination, treatment and rehabilitation opportunities to patients with serious musculoskeletal conditions. The clinic owes its leading international reputation to its unique combination of specialized medical services. The hospital's carefully-balanced, interdisciplinary network brings together under one roof medical specialties including orthopedics, paraplegiology, radiology, anesthesiology, rheumatology, and physical medicine. More information about Balgrist University Hospital is available at www.balgrist.ch.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The Company recently reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has received authorization from the FDA to initiate a Phase I/II clinical trial in dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand.

SOURCE: StemCells

[Fruehrentner]

StemCells announces HuCNS-SC product positive Phase I/II interim data

04 September 2012

StemCells has announced positive six-months interim data from a Phase I/II clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells), designed for the treatment of chronic spinal cord injuries.


The Phase I/II trial, which transplanted first cohort including three patients with a dose of 20 million cells at the thoracic site of injury having no neurological function, is designed to assess both safety and preliminary efficacy of HuCNS-SC product.

The trial is also designed to assess preliminary efficacy based on clinical endpoints such as changes in sensation, motor function and bowel/bladder function.

The results showed that there were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first six months following transplantation.

Two of the patients were observed with changes in sensitivity to touch, heat and electrical stimuli in well-defined and consistent areas below the level of injury, while no changes were observed in the third patient.

University of Zurich Balgrist University Hospital Spinal Cord Injury Center professor and chairman Dr. Curt said the company is intrigued to see that two of the three patients have gained considerable sensory function.

"The gains in sensation have evolved in a progressive pattern below the level of injury and are unanticipated in spinal cord injury patients with this severity of injury, suggesting that the neural stem cells are having a beneficial clinical effect," Curt added.

The company said enrollment for the second cohort is also underway.

[Fruehrentner]

[Schablonski]

Antwort auf Beitrag Nr.: 43.569.991 von Fruehrentner am 05.09.12 10:38:55

spannender Wert z.Zt.

[Fruehrentner]

StemCells, Inc. Achieves Spinal Cord Injury Milestone With First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury

28 Sep 2012

NEWARK, CA, USA I September 27, 2012 I StemCells, Inc. (Nasdaq: STEM) today announced that the first patient with an incomplete spinal cord injury has been enrolled in the Company's Phase I/II clinical trial in chronic spinal cord injury and transplanted with the Company's proprietary HuCNS-SC® neural stem cells. The patient, a Canadian man who suffered a thoracic spinal cord injury from a sports-related accident, was administered the cells yesterday at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation. This is the first patient in the second cohort of the trial, which will be comprised of four patients who retain some sensory function below the level of trauma and are therefore considered to have an incomplete injury.

"This is an important milestone for StemCells and the spinal cord injury community as it is the first time anyone has ever transplanted neural stem cells into a patient with an incomplete injury," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Given the encouraging interim data from the most severely injured patient cohort that we reported earlier this month, testing patients with less severe injury should afford us an even better opportunity to continue to test safety and to detect and assess clinical changes. Unlike the patients in the first cohort, patients with incomplete injuries have retained a degree of spinal cord function that might be even further augmented by transplantation with neural stem cells."

Earlier this month, the Company reported that interim six-month data from the first patient cohort in the Phase I/II clinical trial continued to demonstrate a favorable safety profile, and showed considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. Patients in the first cohort all suffered a complete injury to their spinal cord, leaving them with no neurological function below the level of injury. Following transplantation with HuCNS-SC cells, there were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first six months after transplantation. Changes in sensitivity to touch, heat and electrical stimuli were observed in well-defined and consistent areas below the level of injury in two of the patients, while the third patient remained stable. Importantly, the changes in sensory function were confirmed objectively by measures of electrical impulse transmission across the site of injury, each of which correlated with the clinical examination.


About the Spinal Cord Injury Clinical Trial

The Phase I/II clinical trial of StemCells, Inc.'s HuCNS-SC® purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment, and their injuries must have occurred within three to twelve months prior to transplantation of the cells. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor function and bowel/bladder function. The Company has dosed the first patient cohort, all of whom have injuries classified as AIS A according to the American Spinal Injury Association Impairment Scale (AIS). In AIS A injuries, there is no neurological function below the injury level. The second cohort will be patients classified as AIS B, in which there is some preservation of sensory or motor function below the injury level. The third cohort will be patients classified as AIS C, in which there is some preservation of both sensory and motor function.

All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and each of the patients will be invited to enroll into a separate four year observational study after completing the Phase I/II study.

The trial is being conducted at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation, and is open for enrollment to patients in Europe, Canada and the United States. Enrollment for the second cohort is now underway. If you believe you may qualify and are interested in participating in the study, please contact the study nurse either by phone at [phone] or by email at [e-mail].

Additional information about the Company's spinal cord injury program can be found on the StemCells, Inc. website at http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm" target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm," target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm, including video interviews with Company executives and independent collaborators.

About Balgrist University Hospital

Balgrist University Hospital, University of Zurich is recognized worldwide as a highly specialized center of excellence providing examination, treatment and rehabilitation opportunities to patients with serious musculoskeletal conditions. The clinic owes its leading international reputation to its unique combination of specialized medical services. The hospital's carefully-balanced, interdisciplinary network brings together under one roof medical specialties including orthopedics, paraplegiology, radiology, anesthesiology, rheumatology, and physical medicine. More information about Balgrist University Hospital is available at www.balgrist.ch.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.

SOURCE: StemCells

[Fruehrentner]

(statischer chart)

[Fruehrentner]

die letzten 6 Monate (stat. chart)

[Fruehrentner]

StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related Macular Degeneration

NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States. AMD afflicts approximately 30 million people worldwide and is the leading cause of vision loss and blindness in people over 55 years of age.

"This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Studies in the relevant animal model demonstrate that the Company's neural stem cells preserve vision in animals that would otherwise go blind and support the therapeutic potential of the cells to halt retinal degeneration. Unlike others in the field, we are looking to intervene early in the course of the disease with the goal of preserving visual function before it is lost."

David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory and principal investigator of the study, added, "We are excited to be working with StemCells on this ground breaking clinical trial. There currently are no effective treatments for dry AMD, which is the most common form of the disease, and there is a clear need to explore novel therapeutic approaches."

In February 2012, the Company published preclinical data that demonstrated HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD. The data was published in the international peer-reviewed European Journal of Neuroscience.


About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the United States with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at [phone].

About HuCNS-SC Cells

StemCells' proprietary product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing clinical studies.

About The Retina Foundation of the Southwest

The Retina Foundation of the Southwest is an independent, non-profit research organization located in Dallas, Texas. The Foundation has grown into one of the leading independent vision research centers in the United States, with a staff dedicated to finding the causes, treatments and potential cures for blinding eye diseases. Along the way, the Foundation has made a life changing difference in the lives of patients who suffer from retina related diseases. Patients are referred by ophthalmologists from around the world, and because the center is funded by philanthropic and federal grants, patient services are entirely free. The Foundation is a volunteer-driven organization dedicated to making a difference in people's lives by improving their vision – no matter what their age or financial status. Scientists and clinicians at the Foundation use the power of modern technology to understand the intricacy of retinal function and conduct studies of hereditary and acquired blinding retinal disorders, including retinitis pigmentosa and age-related macular degeneration. Other studies address eye disorders affecting the sight of infants and children, including hereditary eye diseases, cataracts, prematurity and the consequences of eye muscle imbalance. Further information about the RFSW is available at http://www.retinafoundation.org.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In March 2012, the Company reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim safety data for the first patient cohort. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.

[lunatics]

Auch sehr spannend: Neuralstem CUR





Cell Therapy Treatments in Development

ALS
NSI-566
Ongoing Phase I, II trial expected to commence in 4Q2012. More
zu ALS
http://www.muskelzentrum.kssg.ch/home/informationen_fuer/kra…

Preclinical program:
Ischemic Stroke
Spinal Cord Injury
Glioblastoma (Brain Cancer)
Multiple Sclerosis
Optic Neuritis
Alzheimer’s Disease
Traumatic Brain Injury
Peripheral Nerve Injury

[schiedo]

Hier entsteht ganz was Großes.

Die Fantasie wird den Kurs stark treiben - Stammcellen ist die Zukunft......

[lunatics]

Zitat von schiedo: Hier entsteht ganz was Großes.

Die Fantasie wird den Kurs stark treiben - Stammcellen ist die Zukunft......

News über Neuralstem.
http://finance.yahoo.com/news/fda-approves-neuralstem-treat-…

[lunatics]

StemCells and R Biomedical Develop and Commercialize Reagents for Human iPS Cell Research !

Details auf:
http://finance.yahoo.com/news/stemcells-inc-partners-r-biome…

[Schablonski]

Antwort auf Beitrag Nr.: 43.768.310 von lunatics am 30.10.12 21:47:35

bin auch schon gespannt auf den Start heute :-)

[lunatics]

2013: Year of the Stem Cell

Interessanter Artikel:
http://www.theatlantic.com/health/archive/2012/12/2013-year-…

[sufenta]

Antwort auf Beitrag Nr.: 43.974.285 von lunatics am 02.01.13 15:44:07

Schöner "return" heute..knapp 10% mit Tageshöchstkurs und entsprechendem Volumen...bin gespannt auf 2013...(@ lunatics: mein EK in US knapp 2,40)...und auch interessant:

http://seekingalpha.com/article/1097861-2012-breakthroughs-i…

Insgesamt aber unglaublich viel/zu viel Auswahl an Biotech insgesamt...da stellt sich die Frage, ob nicht besser ein Invest in ein Biotech-Fond mit US-Ausrichtung.

Nebenbei: Werde diese Woche noch in Nationstar Mortgage Holding einsteigen...hoffe, dass sie bis dahin nicht über die 40 springen...


Grüsse,s.

[sufenta]

Antwort auf Beitrag Nr.: 43.992.525 von sufenta am 08.01.13 00:03:59

Grund/einer der Gründe des Anstiegs?


http://www.aerzteblatt.de/nachrichten/52929

[Fruehrentner]

Antwort auf Beitrag Nr.: 43.992.627 von sufenta am 08.01.13 01:39:10

Glaube ich kaum, das war ein Grundlagenexperiment.

[sufenta]

Antwort auf Beitrag Nr.: 43.997.538 von Fruehrentner am 08.01.13 23:22:52

Natürlich war's das. Aber danke trotzdem für die Antwort.

[Fruehrentner]

Meldung aus der Stammzellbranche:


MESOBLAST’S NEOFUSE STEM CELL PRODUCT SHOWS POSITIVE RESULTS IN PHASE 2 LUMBAR SPINAL FUSION TRIAL Print
11 Jan 2013

Results support progression of clinical development to Phase 3

Key points:

• Phase 2 trial results using Mesoblast’s allogeneic, or “off-the-shelf”, Mesenchymal Precursor Cells (MPCs) demonstrated rates of fusion success that were comparable to the gold standard bone autograft

• MPCs were well tolerated with no cell-related serious adverse events and no evidence of any ectopic bone formation

• At 12 months, fusion was achieved in 85.7% and 62.5% of patients in the low and high MPC treatment groups compared to 75% of patients who received bone autograft

• Significant improvements in low back pain scores and total disability index were seen in both MPC groups and were comparable to those receiving bone autograft

• Those receiving MPCs had 30-43% less blood loss during the surgical procedure than those receiving bone autograft (p<0.05)

• These results indicate that lumbar vertebral fusion using allogeneic MPCs is as effective as bone autograft

• Eliminating the need for an autograft bone harvest will avoid the risks of this procedure, including pain, infection and blood loss.

MELBOURNE, Australia I January 11, 2012 I Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that its Phase 2 clinical trial for lumbar spinal fusion had successfully met its safety and efficacy endpoints.

The results suggest that Mesoblast’s NeoFuse product comprising allogeneic Mesenchymal

Precursor Cells (MPCs) is as effective for interbody lumbar fusion as the gold standard, bone autograft, without the need for a second surgical procedure and its attendant morbidity risks. These results support the progression of clinical development of NeoFuse to a Phase 3 trial in interbody lumbar fusion.

The results were highlighted during a presentation to the 31st annual JP Morgan Healthcare Conference in San Francisco by Mesoblast Chief Executive Professor Silviu Itescu.

Twenty four (24) patients were enrolled and randomized over 5 sites in the United States with 8 patients in each treatment arm – bone autograft standard of care (Control), 25 million MPCs (25M), and 75 million MPCs (75M). Patients underwent the surgical procedure, one or two level fusions using a posterior approach to the spine, and were evaluated for safety and efficacy. The median follow-up times for the three treatment groups were 23.9, 20.7, and 22.9 months for the bone autograft, 25M, and 75M groups, respectively.

MPCs were well tolerated with no cell-related serious adverse events and no ectopic bone formation at all. Notably, MPC treated groups had 30-43% lower mean estimated blood loss during surgery compared to the autograft treatment group (p<0.05 for the 25M group).

At 12 months, fusion was achieved in 85.7% of patients in the 25M treatment group compared to 62.5% in the 75M and 75% in the control patient groups.

Overall, patients from all three treatment groups had a clinically significant and comparable decrease in low back and leg pain, assessed on the Visual Analogue Scale and functional improvement, assessed by the Oswestry Disability Index questionnaire.

Dr Randall Dryer, an orthopedic surgeon with the Central Texas Spine Institute and an investigator in Mesoblast’s study, said: “For patients whose spinal discs have degenerated too extensively for repair, bony fusion of adjacent vertebra is the primary option to eliminate chronic and debilitating pain.

“Other than autograft, there is no approved product for posterior spinal fusion, a surgical approach which accounts for 62% of all lumbar fusion procedures. There is a critical unmet need for new technologies to achieve fusion that are safe, effective, and that eliminate the need for bone autograft.

“Based upon my experience in the Phase 2 study, Mesoblast’s cells may provide a significant and valuable option to achieve fusion in patients with severe spinal disc degeneration and these results warrant progressing to a Phase 3 study,” Dr Dryer added.

According to Millennium Research Group, in the United States there were approximately 380,000 lumbar spinal fusion procedures performed in 2012. They estimate the overall worldwide market for bone graft substitutes to be nearly $1.6 billion dollars in 2012 with the majority of bone graft revenues, approximately 70%, coming from spinal fusion procedures.

Mesoblast plans to initiate a Phase 3 trial for interbody lumbar fusion later this year, with patients to be enrolled across multiple sites in the United States, Europe and Australia.


Mesoblast Limited

Mesoblast Limited is a world leader in the development, manufacture, and commercialization of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for a broad range of major clinical diseases, including inflammatory and immunologic conditions, diabetes and its complications, orthopedic spine conditions, and cardiovascular disorders. www.mesoblast.com

SOURCE: Mesoblast

[sufenta]

Antwort auf Beitrag Nr.: 44.021.218 von Fruehrentner am 14.01.13 22:16:35

Hallo,

Danke für den Beitrag,

hier noch eine schöne, weil kurze Zusammenfassung:


http://seekingalpha.com/article/1112911-the-race-to-cure-spi…

einerseits über den Therapiebereich der Spinal cord injuries und andererseits grob über STEM, CUR und InVivoTherapeutics

CUR "soeben" mit Studienbeginn nach FDA-Zulassung und entsprechendem Kurssprung

Frage mich aber, warum die Fallzahlen so immens klein sind?!

Bei CUR werde ich wohl mit ner Miniposi einsteigen, InVivo muss ich noch genauer schauen.

M.E., und deswegen mein Engagement in STEM, deren u.a. wichtigstes "Feld": die AMD, sollte hier irgendein Mini-Resultat positiv ausfallen, dann sind mehrere 100% bis gar 1000% innerhalb weniger Tage fast garantiert.

Jemand eine andere Meinung?


Grüsse,s.

[sufenta]

Antwort auf Beitrag Nr.: 44.026.481 von sufenta am 16.01.13 02:46:36

Achja, und nicht zu vergessen, ebenfalls STEM betreffend:

We remind investors that StemCells Inc was awarded a $20 million grant from the California Institute for Regenerative Medicine in July 2012. The goal is to file a U.S. IND in the next four years.

Am Ende des o.g. Artikels

[sufenta]

YES and YOO:

http://finance.yahoo.com/news/stemcells-inc-announces-first-…

Bin auf DEN Jump gespannt, wenn/sollten die AMD-Ergebnisse veröffentlicht werden!

Noch jemand investiert?

[Fruehrentner]

Antwort auf Beitrag Nr.: 44.131.938 von sufenta am 12.02.13 16:51:04

http://finance.yahoo.com/news/stemcells-inc-announces-first-…


Investiert nicht, aber auf watch list.

Danke für den link.

[schiedo]

Ein neuer Aufwärtstrend hat begonnen.....

[Stockfinder]

Die Stammzellenforschung wird in den kommenden Monaten erste komerzielle Erfolge feiern. Stemcells wird dabei in der ersten Reihe sitzen. Eebenfalls nicht zu unterschätzen, Athersys Inc.

Beide Firmen sind aktuell massiv unterbewertet.

[schiedo]

"Kleine Unternehmen sind Hubs von Future Profit in der Regenerativen Medizin: Gil Van Bokkelen"
Auszug aus dem Artikel:

GVB: Ich denke, es wird eine große Rolle spielen. Lassen Sie mich klar sein. Ich sage nicht, dass die Zelltherapie kann nicht eine tiefgreifende Rolle dabei beschädigt oder verletztes Gewebe zu ersetzen. Wir sehen bereits einige ziemlich aufregende Beispiele für das, was Patienten, die unter Verletzung des Rückenmarks leiden profitieren könnten. Zum Beispiel, StemCells Inc. (STEM: NASDAQ) beginnt, einige sehr ermutigend, aber noch sehr früh, Daten über den menschlichen neuronalen Stammzellen Kandidaten bei Patienten mit Rückenmarksverletzungen zu generieren. Wenn das Unternehmen erfolgreich erweitert diese Arbeit mit zusätzlichen Studien, dann Investoren und Patienten sehen konnte ziemlich spannende Dinge zum Tragen kommen.

Aber ich glaube, Ihre Frage zu beantworten, dass die parakrine Effekte von Stammzellen, dh ihre Fähigkeit, Faktoren, die direkt ausdrücken als Reaktion auf erhebliche Gewebeschädigung und die daraus resultierende Entzündung, hat sich im vergangenen Jahrzehnt als wichtiger Bestandteil der therapeutischen Wirksamkeit entstanden zell-basierte Therapien.

Es besteht die Möglichkeit, beide Endpunkte zu erreichen. Verabreichen Zellen können eine dynamische, wirkstoffartiger Ereignis sein, wo die Zellen nicht dauerhaft einprägen sondern sind um für Tage bis Wochen um Gewebereparatur und Heilung helfen, dann Löschen des Körpers als würde ein Medikament oder herkömmliche biologische. Dann gibt es das Potenzial, tatsächlich ergänzen, ersetzen oder zu regenerieren bestimmte Arten von Gewebe. Diese sind ein unglaublich leistungsfähiges Set von Fähigkeiten, die, ehrlich gesagt, nie vernünftigerweise erwarten zu erreichen mit traditionellen, Pharma-basierte Ansätze in den meisten Bereichen konnte.

TLSR: Sie erwähnten StemCells Inc., die dauerhaft Transplantation von adulten oder differenzierten Stammzellen embryonalen Ursprungs in den Gehirnen von Patienten mit lysosomalen Speicherkrankheiten gezeigt hat. Dies hat bei der Autopsie wurden durch Bestimmung, dass ein transplantierten Spender Neuron einer unterschiedlichen Genotyps als die des Empfängers Patient war erwiesen. Doch mit all dieser aufregenden Technologie hat StemCells Inc. ein $ 75M Marktkapitalisierung. Neuralstem Inc. (CUR)
Sentiment: Strong Buy

[Schablonski]

Wer hat den da heute 6000 Stück zu 1,70 in S erworben. Alle Achtung !

[sufenta]

Antwort auf Beitrag Nr.: 44.656.289 von Schablonski am 16.05.13 20:56:08

Jetzt kaufen, 5 Jahre liegen lassen. Denke dieses Jahr noch die 3$.

[Schablonski]

Die Zahlen scheinen gut anzukommen, nachbörslich 1,84 RT

[Fruehrentner]

StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America

First Subject in Canada Transplanted at the University of Calgary

NEWARK, CA, USA, 10.January 2014

StemCells, Inc. (STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC(R) human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America.

This expansion from a single-site, single-country study to a multi-site, multi-country program accelerates the current trial, which should complete enrollment of the remaining three patients this quarter, and pave the way for a controlled Phase II efficacy study that StemCells, Inc. plans to initiate mid-year to further investigate its HuCNS-SC product candidate as a treatment for spinal cord injury.

"With this transplantation in Canada, we have the first international trial investigating neural stem cells for spinal cord injury," said Stephen Huhn, M.D., FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc. "The 12-month data from the first cohort has demonstrated a favorable safety profile, and sensory gains first detected in two of the three subjects at the six-month assessment have persisted. The third subject remains stable. We are extremely encouraged with the progress of our spinal cord injury program and the transition into an international study will accelerate completion of enrollment."

Steve Casha, M.D., Ph.D., FRCSC, the principal investigator at the University of Calgary, added, "We are proud to be the first center to enroll a subject in North America. This important research is yielding critical insight into the use of stem cells in treating spinal cord injury patients. The results should serve as a solid foundation for the Company's planned Phase II controlled efficacy study and represents an important step in the development of this promising technology."

"We have closely followed the conduct of the StemCells, Inc. trial at the University of Zurich, under the direction of Dr. Armin Curt," said Michael Fehlings M.D., Ph.D., FACS, FRCSC. Dr. Fehlings is Medical Director of the Krembil Neuroscience Centre, Professor of Neurosurgery at the University of Toronto, head of the Spinal Program at the Toronto Western Hospital, and principal investigator for the trial at the University of Toronto. "There is a large unmet medical need for treatments in spinal cord injury. The opening of sites in North America is great news for the worldwide community of patients and their families, as well as for researchers. There is a strong rationale to explore novel therapeutic approaches to treating spinal cord injury, and we are pleased to be working with StemCells at the forefront of this trailblazing study."

[nikodimi]

http://seekingalpha.com/article/2069123-stemcells-inc-and-ad…

Bin durch diesen Artikel auf STEM aufmerksam geworden und habe eine kleine Anfangsposition initiert..

[Fruehrentner]

Antwort auf Beitrag Nr.: 46.581.957 von nikodimi am 07.03.14 09:44:14

http://seekingalpha.com/article/2069123-stemcells-inc-and-ad…


danke für den link

[Fruehrentner]

StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury
Significant Sensory Gains Observed in Additional Patients

NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) --

StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.

The presentation included the first data on AIS B subjects to be transplanted in the Phase I/II chronic spinal cord injury trial with the HuCNS-SC®cells. In contrast to AIS A patients who have no mobility or sensory perception below the point of injury, AIS B subjects are less severely injured, they are paralyzed but retain sensory perception below the point of injury. Two of the three AIS B patients had significant gains in sensory perception and the third remained stable. The interim results also continue to confirm the favorable safety profile of the cells and the surgical implant procedure.

The presentation included data from a total of five new subjects with a minimum six month follow up. In total, the Company has now reported clinical updates on a total of eight of the twelve patients enrolled in its Phase I/II clinical trial using the Company's proprietary HuCNS-SC (purified human neural stem cells) platform technology for chronic thoracic spinal cord injury.

"Thoracic spinal cord injury was chosen as the indication in this first trial primarily to demonstrate safety. This patient population represents a form of spinal cord injury that has historically defied responses to experimental therapies and is associated with a very high hurdle to demonstrate any measurable clinical change. Because of the severity associated with thoracic injury, gains in multiple sensory modalities and segments are unexpected, and changes in motor function are even more unlikely," said Dr. Armin Curt, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich. "In contrast, the cervical cord, which controls more motor function, may represent a patient population in which motor responses to transplant may be more readily anticipated."

"We are seeing multi-segmental gains and a return of function in the cord in multiple patients. This indicates something that was not working in the spinal cord, now appears to be working following transplantation. This is even more significant because of the time that has elapsed from the date of injury, which ranges from 4 months to 24 months across the subjects with sensory gains," said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research at StemCells, Inc. "These results are exciting with respect to the expansion of this trial into patients with cervical injury because even a gain of one to two segments in cervical spinal cord injury patients can allow for additional function in the upper extremities."

A copy Dr. Armin Curt's presentation can be found on the StemCells, Inc. website at:

http://www.stemcellsinc.com/Presentations/ASIA_FINAL.pdf

[Fruehrentner]

StemCells, Inc. Advances Clinical Trial in Age-Related Macular Degeneration to Final Cohort

Phase I/II AMD Trial on Track to Complete Enrollment in June


NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Each of the eight patients in this second cohort will receive a dose of 1 million stem cells into the most affected eye.

"We are very pleased with the rate of progress being made towards our goal of completing enrollment in this study by the end of this quarter," said Stephen Huhn, M.D., FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc. "We look forward to releasing the first interim results from this study next month and are planning to initiate a controlled Phase II proof-of-concept study later this year."


About Geographic Atrophy of Age-Related Macular Degeneration

An estimated 10 million people in the U.S. either have age-related macular degeneration (AMD) or are at substantial risk for receiving the diagnosis, according to the Foundation Fighting Blindness. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s and gradually progresses to destroy central vision. Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. Overall, about 85% of patients with AMD suffer from the dry form of the disease, the advanced form of which is referred to as "geographic atrophy."

About the Trial

The Phase I/II trial evaluates the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The investigation is divided into two sequential cohorts. Subjects are enrolled into each cohort based on best-corrected visual acuity (BCVA), as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. Patients with BCVA of less than or equal to 20/400 in the study eye were enrolled in Cohort I. Patients with less severe BCVA of 20/320 to 20/100 in the study eye are being enrolled in Cohort II. Cohort I consists of four subjects who were each transplanted with 200,000 stem cells, followed by four subjects who have each been transplanted with 1 million cells. Cohort II will consist of eight subjects who will undergo transplant with 1 million cells. The HuCNS-SC cells are administered by a single injection into the space behind the retina in the most affected eye. Patients' vision is being evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations are being performed at predetermined intervals over a one-year period to assess safety and signs of vision improvement. Patients will be followed for an additional four years in a separate observational study.

The trial is currently enrolling patients at five centers. Patients interested in participating in the study should contact one of these centers directly:
Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA – [phone]
New York Eye and Ear Infirmary, New York, NY – [phone]
Retina Foundation of the Southwest, Dallas, Texas – [phone]
Retina Research Institute of Texas, Abilene, TX – [phone]
The Retina-Vitreous Associates Medical Group, Los Angeles, CA – [phone] ext 1243

More information about the StemCells Dry Age Related Macular Degeneration program can be found on the Company website at:

http://www.stemcellsinc.com/Therapeutic-Programs/AMD-and-Retinal-Disorders.htm" target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/AMD-and-Retinal-Disorders.htm

Additional information about the clinical trial is available at:

http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm" target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm

and at the U.S. National Institutes of Health website at:

http://www.clinicaltrials.gov/ct2/show/NCT01632527?term=stem…

About HuCNS-SC Cells

StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies of its proprietary HuCNS-SC cells. StemCells clinicians and scientists believe that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. The Company's preclinical research established that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. The HuCNS-SC platform technology is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's platform technology, HuCNS-SC® cells (purified human neural stem cells), is currently in clinical development as a potential treatment for a broad range of central nervous system disorders. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.

[Fruehrentner]

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial

NEWARK, CA, USA I June 19, 2014 I

StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.

Interim trial results show a 65 percent reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 percent reduction in the rate of GA when compared to the control eye.

GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium. This degeneration is the cause of vision loss in dry AMD.

Interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark, also referred to as "contrast sensitivity."

Contrast sensitivity was improved in four of the seven patients and remained stable in the other three patients.

The interim analysis is based on a minimum follow up of at least 6 months and demonstrates a favorable safety profile for administration of the HuCNS-SC cells into the sub-retinal space of the study eye.

"The interim data are very encouraging from two separate perspectives. First, the reduction in the rate of geographic atrophy suggests the HuCNS-SC cells are affecting the underlying cause of AMD. Secondly, the data demonstrates there are increases in contrast sensitivity, which is a vital aspect of visual function," said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research and chief medical officer at StemCells, Inc. "Impacting the progression of GA and enhancing visual function could have a very meaningful impact on the quality of life for AMD patients and the results to date strongly support our plans to initiate a randomized, controlled, Phase II proof-of-concept trial later this year."

"These interim results have exceeded our expectations at this stage of the trial," said David Birch, Ph.D., chief scientific and executive officer of the Retina Foundation of the Southwest in Dallas, Texas. "These results are particularly interesting given that the first cohort of patients had significant visual impairment and baseline GA. The next cohort of patients will have less impairment and we look forward to learning even more as we analyze data from the patients in the second half of the trial."

StemCells, Inc. will host a conference call and webcast to discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD, after market close today, Thursday, June 19, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time).


About Age-Related Macular Degeneration and Geographic Atrophy

An estimated 10 million people in the United States either have age-related macular degeneration (AMD) or are at substantial risk for receiving the diagnosis, according to the Foundation Fighting Blindness. AMD, a degenerative retinal disease that typically strikes adults in their 50s or early 60s and gradually progresses to destroy central vision, is the leading cause of blindness in adults over 55 years of age in the developed world. Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. Approximately 85-90 percent of AMD cases are the "dry" type of the disease, the advanced form of which is referred to as "geographic atrophy."

About the Trial

The Phase I/II trial evaluates the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. Patients with dry AMD had to have evidence of GA to be eligible for inclusion. The investigation is divided into two sequential cohorts. Subjects are enrolled into each cohort based on best-corrected visual acuity (BCVA), as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. Patients with BCVA of less than or equal to 20/400 in the study eye were enrolled in Cohort I. Patients with less severe BCVA of 20/320 to 20/100 in the study eye are being enrolled in Cohort II. Cohort I consists of four subjects who were each transplanted with 200,000 stem cells, followed by four subjects who have each been transplanted with 1 million cells. Cohort II will consist of eight subjects who will undergo transplant with 1 million cells. The HuCNS-SC cells are administered by a single injection into the space behind the retina in the most affected eye. Patients' vision is being evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations are being performed at predetermined intervals over a one-year period to assess safety and signs of vision improvement. Patients will be followed for an additional four years in a separate observational study.

The trial enrolled at five locations:

Retina Foundation of the Southwest, Dallas, Texas

Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA

New York Eye and Ear Infirmary, New York, NY

Retina Research Institute of Texas, Abilene, TX

Retina-Vitreous Associates Medical Group, Los Angeles, California

More information about the StemCells Dry Age Related Macular Degeneration program can be found on the Company website at: http://www.stemcellsinc.com/Therapeutic-Programs/AMD-and-Retinal-Disorders.htm" target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/AMD-and-Retinal-Disorders.htm

Additional information about the clinical trial is available at: http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm" target="_blank" rel="nofollow ugc noopener">http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at the U.S. National Institutes of Health website at: http://www.clinicaltrials.gov/ct2/show/NCT01632527?term=stem…

About HuCNS-SC Cells

StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies of its proprietary HuCNS-SC cells. StemCells clinicians and scientists believe that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the central nervous system (CNS). Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. The Company's preclinical research established that HuCNS-SC cells can be directly transplanted in the CNS with no sign of tumor formation or adverse effects. The HuCNS-SC platform technology is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's platform technology, HuCNS-SC® cells (purified human neural stem cells), is currently in clinical development as a potential treatment for a broad range of central nervous system disorders. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.

[ooy]

Lesezeichen, Danke...

[can2]

Die Aufmerksamkeit wird wieder größer bei Stemcells!





Stemcells

Equities researchers at Brinson Patrick assumed coverage on shares of Stemcells (NASDAQ:STEM) in a research report issued on Wednesday. The firm set an “outperform” rating and a $7.00 price target on the stock. Brinson Patrick’s price objective indicates a potential upside of 250.00% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group raised their price target on shares of Stemcells from $2.50 to $5.00 in a research note on Friday, June 20th. They now have a “buy” rating on the stock. Separately, analysts at Chardan Capital reiterated a “positive” rating on shares of Stemcells in a research note on Tuesday, June 17th.

Stemcells (NASDAQ:STEM) opened at 2.00 on Wednesday. Stemcells has a one year low of $1.15 and a one year high of $2.34. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $1.43. The company’s market cap is $111.0 million.

Stemcells (NASDAQ:STEM) last released its earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Analysts expect that Stemcells will post $-0.60 EPS for the current fiscal year.

StemCells, Inc (NASDAQ:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry.


Quelle:
http://www.americanbankingnews.com/2014/07/02/stemcells-now-…

[can2]

Die Aktie war mal echt sehr populär, wird Zeit an alte Zeiten wieder anzuknüpfen!

[can2]

Google Übersetzer verwendet:

Aktien Forscher an Brinson Patrick angenommen Abdeckung auf Aktien der Stemcells (NASDAQ: STEM) in einem Research-Bericht am Mittwoch veröffentlicht. Das Unternehmen setzen ein "outperform"-Rating und einem Kursziel von 7,00 $ für die Aktie. Brinson Patrick Kursziel zeigt eine Aufwärtspotenzial von 250,00% aus der Aktie vorherigen Nähe.

Andere Aktien-Analysten haben auch vor kurzem Berichte über das Lager. Die Analysten der Maxim Group hat ihr Kursziel für Aktien der Stemcells ab $ 2,50 bis $ 5,00 in einer Research Note am Freitag, 20. Juni. Sie haben jetzt ein Rating "buy" für die Aktie. Getrennt, Analysten von Chardan Hauptstadt bekräftigte eine "positive" Bewertung auf Aktien der Stemcells in einer Research Note am Dienstag 17. Juni.

Stemcells (NASDAQ: STEM) eröffnet um 2.00 am Mittwoch. Stemcells hat einen Ein-Jahres-Tief von $ 1,15 und ein Jahr Hoch von $ 2.34. 50-Tage-Durchschnitt der Aktie ist 1,57 $ und seine 200-Tage-Durchschnitt ist 1,43 $. Marktkapitalisierung des Unternehmens ist es 111,0 Millionen Dollar.

Stemcells (NASDAQ: STEM) zuletzt am Mittwoch 14. Mai veröffentlicht die Ergebnisdaten . Das Unternehmen berichtet ($ 0.14) Ergebnis je Aktie (EPS) für das Quartal, fehlt der Konsensschätzung von ($ 0.12) von 0,02 $. Das Unternehmen hatte einen Umsatz von 0.340.000 $ für das Quartal, verglichen mit der Konsensschätzung von 0,24 Millionen Dollar. Im gleichen Quartal im Vorjahr erzielte das Unternehmen ($ 0,17) Ergebnis je Aktie. Analysten erwarten, dass Stemcells wird für das laufende Geschäftsjahr eine EPS -0,60 $.

StemCells, Inc. (NASDAQ: STEM) ist in der Forschung, Entwicklung und Vermarktung von Stammzelltherapeutika und damit verbundene Basistechnologien für Wissenschaft und Industrie tätig.

Schönen Abend noch! ;-)

[Schablonski]

Antwort auf Beitrag Nr.: 47.248.728 von can2 am 02.07.14 17:08:55

Ja, das merke ich auch. Hatte ich lange im Depot mit Null Bewegung, aber jetzt glaube ich beim ersten Anstieg viel zu früh verkauft
Da ist gerade richtig Volumen drin und ich glaube das geht erst richtig los
Viel Erfolg.

[can2]

Ich bin gestern wieder eingestiegen, hatte mich auch geärgert etwas, weil hin und her die Taschen nur leer macht allzu oft. Ich schätze die Aktie wird sich wieder bei einigen Dollars einpendeln, denn sie wurde quasi ungespitzt in den Boden versenkt. Nun kommt wieder Ernüchterung und die Aufmerksamkeit wird an Dynamik wohl zunehmen?

[/url]

[can2]

Normalerweise ist Stemcells sehr dynamisch in der Vergangenheit gewesen, das kann alles noch kommen...bin gespannt...

[gbecker]

So bin jetzt auch dabei. Erhoffe mir schon einiges von Stemcell. Auf geht`s!

[can2]

Könnte etwas mehr steil rauf gehen mal wieder! :-)

[can2]

Sag mal handelt die Masse hier mehr an der Heimatbörse oder hier in Deutschland?

[can2]

Börse Nasdaq
Aktuell 2,3399 USD
Zeit 03.07.14 17:53
Diff. Vortag +2,18%
Tages-Vol. 10,15 Mio.
Gehandelte Stück 4,42 Mio.
Geld 2,33
Brief 2,34
Zeit 03.07.14 17:53
Spread 0,43%

Geld Stk. 60.000
Brief Stk. 2.800

[can2]

Wieso kein Handel mehr, seit gestern Abend stagniert es und der Spread wechselte einige Male...werden die sich nicht einig oder was soll das???


Kursdaten
Börse Nasdaq
Aktuell 2,34 USD
Zeit 03.07.14 19:00
Diff. Vortag +2,18%
Tages-Vol. 12,25 Mio.
Gehandelte Stück 5,35 Mio.
Geld 2,27
Brief 3,47
Zeit 03.07.14 23:00
Spread 34,58%
Geld Stk. 3.000
Brief Stk. 3.000

[can2]

Der Independence Day - Feiertag...:-)

[NurFundamentalesIstBares]

-derzeit recherchiere ich noch nach den Gründen für die Dynamik gestern-

bisher habe ich aber noch nichts gefunden. Weder in boards noch in news channels. Am 27.4.15 gibt's eine Stammzellenkonferenz in Boston, eventuell wird dort etwas Revolutionäres vorgestellt.

Da mir der Ausbruch gestern zu stark erschien, bin ich dann doch mal mit einer Posi bei 1.20$ reingegangen. Der Anstieg lässt sich nicht nur mit der Biotech-Hausse erklären aus meiner Sicht, da steht irgendwas ziemlich großes bevor. nmM

Auf jeden Fall mal den Chart im Auge behalten:

[gbecker]

Antwort auf Beitrag Nr.: 49.232.789 von NurFundamentalesIstBares am 04.03.15 07:52:14

Ja sieht so as als ob sich was tut hier. Aber diese Dinger sind alle mit Vorsicht zu geniessen. Aber werde auch mal bisschen nachlegen um EK runterholen. War bei 1.70 eingestiegen und ab da ging es nur runter

[gbecker]

Antwort auf Beitrag Nr.: 49.251.638 von gbecker am 05.03.15 17:33:00

Hier frisch aus der Presse - Q4 und 2014 results

http://globenewswire.com/news-release/2015/03/16/715657/1012…

[gbecker]

Antwort auf Beitrag Nr.: 49.352.471 von gbecker am 17.03.15 15:55:59

Mal gespannt wie die heutige Presentation bei den Investoren ankommt

StemCells Inc. (NASDAQ:STEM) shares decreased -4.03% in last trading session and ended the day at $0.65. STEM Gross Margin is 90.00% and its return on assets is -183.00%. StemCells Inc. (NASDAQ:STEM) quarterly performance is -40.54%. StemCells, Inc. (NASDAQ:STEM) announced that management presented on the Company’s programs, pipeline and operations at the 2015 Marcum MicroCap Conference. Management on Thursday, May 28, at The Grand Hyatt New York Hotel, in the Imperial room, located at 109 E 42nd Street in New York City.

[lunatics]

Heftiger Misserfolg stürzt STEM in die Krise. -80%

http://www.siliconbeat.com/2016/05/31/bay-area-biotech-compa…